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Abstract of  the Dissertation 
 
 
 
The Association between Traumatic Brain Injury and Alzheimer’s Disease: Mouse 
Models and Potential Mechanisms 
by 
Hien Thuy Tran 
Doctor of Philosophy in Biology and Biomedical Sciences (Neurosciences) 
Washington University in St. Louis, 2011 
Professor David L Brody 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized 
pathologically by progressive neuronal loss, extracellular plaques containing the amyloid-β 
(Aβ) peptides, and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau 
proteins. Aβ is thought to act upstream of tau, affecting its phosphorylation and therefore 
aggregation state.  One of the major risk factors for AD is traumatic brain injury (TBI).  
Acute intra-axonal Aβ and diffuse extracellular plaques occur in approximately 30% of 
human subjects following severe TBI. Intra-axonal accumulations of total and phospho-tau 
and less frequently NFTs have also been found in these patients.  Due to the lack of an 
appropriate small animal model, it is not completely understood if and how these acute 
accumulations contribute to subsequent AD development. Furthermore, mechanisms 
underlying Aβ and tau pathologies post TBI have not been thoroughly investigated, nor is it 
known if Aβ also acts upstream of tau in this context. 
 
Here we report that controlled cortical impact TBI in 3xTg-AD mice resulted intra-
axonal Aβ accumulations and increased phospho-tau immunoreactivity within hours and up 
to 7 days post TBI. Given these findings, we investigated the relationship between Aβ and 
tau pathologies following trauma in this model by systemic treatment of Compound E to 
inhibit γ-secrectase activity, a proteolytic process required for Aβ production. Compound E 
treatment successfully blocked post-traumatic Aβ accumulation in these injured mice. 
However, tau pathology was not affected. Furthermore, rapid intra-axonal amyloid-β 
accumulation was similarly observed post TBI in APP/PS1 mice, another transgenic 
Alzheimer’s disease mouse model, and acute increases in total and phospho-tau 
immunoreactivity were also evident in single transgenic TauP301L mice subjected to TBI.  
These data provide further evidence for the causal effects of TBI on acceleration of acute 
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Alzheimer-related abnormalities and the independent relationship between amyloid-β and 
tau in the setting of brain trauma.   
 
We next used the 3xTg-AD TBI model to investigate mechanisms responsible for 
increased tau phosphorylation post brain trauma. We found that TBI resulted in abnormal 
axonal accumulation of a number of kinases found to phosphorylate tau, including protein 
kinase A (PKA), extracellular signal-regulated kinase 1/2 (ERK1/2), cyclin-dependent 
kinase-5 (CDK5), glycogen synthase kinase-3 (GSK-3), and c-jun N-terminal kinase (JNK). 
Notably, JNK was markedly activated in injured axons and colocalized with phospho-tau. 
We therefore treated mice intracerebroventricularly immediately after TBI with a peptide 
inhibitor of JNK, D-JNKi1, which specifically blocks interaction of JNK and its substrates. 
We found that moderate reduction of JNK activity (40%) was sufficient to significantly 
reduce total and phospho-tau accumulations in axons of TBI mice. These data suggest 
targeting JNK pathway may be useful in reducing tau pathology and its adverse effects in the 
setting of brain trauma. 
 
Finally, we investigated whether these acute pathologies negatively contribute to 
long-term neurodegenerative and behavioral deficits, act as a protective response, or play a 
neutral role following TBI. In addition, we sought to understand the role of mutant PS1M146V 
in TBI-induced neurodegeneration. Overall, we found that TBI resulted in chronic axonal 
Aβ pathology in the absence of plaques in injured 3xTg-AD mice. TBI also caused chronic 
tau pathology as evidenced by PHF1 tau staining in both injured 3xTg-AD and PS1 
littermate controls. Furthermore, TBI caused progressive neurodegeneration and 
impairments in spatial learning of injured mice, regardless of genotypes. In summary, these 
data demonstrate a single episode of TBI can have long lasting effects on neuronal functions 
and contributes to cognitive deficits, which are independent of the acute post-traumatic Aβ 
and tau pathologies.
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Chapter 1 
Introduction to Traumatic Brain Injury 
and Alzheimer’s disease 
1.1 Traumatic Brain Injury 
1.1.1 Introduction 
Traumatic brain injury (TBI) is a major public health problem. Annual TBI costs 
are approximately 60 billion in direct medical costs and indirect costs such as lost of 
productivity. It accounts for a third of all injury-related deaths in the U.S alone. Those 
who survive from TBI often suffer from cognitive and behavioral dysfunctions 
(Coronado et al., 2011). As a result, it is not surprising that TBI is a major 
environmental risk factor for subsequent development of dementia of the Alzheimer’s 
type (Mortimer et al., 1991; Plassman et al., 2000; Fleminger et al., 2003). 
TBI, a form of acquired brain injury, occurs when physical forces cause damage 
to the brain and its functions. TBI can result from penetrating head injury or closed-
head injury. Penetrating injury occurs when an object pierces through the skull and 
directly damages the brain matter. Closed-skull injury refers to damage to the brain 
without breaking of the skull. Common causes of TBI are motor vehicle accidents, falls, 
assaults, contact sports, and blast.  
Brain damage following TBI is a result of both primary mechanical disruption of 
brain tissue and secondary injury mechanisms. These delayed/secondary injury 
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processes provide a therapeutic window for lessening the adverse effects of TBI. One 
such delayed process is traumatic axonal injury (TAI), which is also known as diffuse 
axonal injury. TAI refers to the widespread axonal damage observed in many brain 
structures following various injury severities in human and multiple animal models 
(Strich, 1956; Adams, 1982; Gennarelli et al., 1982; Adams et al., 1984; Grady et al., 
1993; Blumbergs et al., 1994; Sherriff et al., 1994b; Blumbergs et al., 1995). TAI is 
believed to contribute to morbidity and cognitive dysfunctions following TBI. As such, 
much of TBI research has focused on mechanisms of TAI and ways to reduce TAI 
following injury.   
1.1.2 Pathology 
Traumatic Axonal Injury 
TAI is a prominent feature of TBI (Strich, 1956; Adams, 1982; Gennarelli et al., 
1982; Adams et al., 1984; Grady et al., 1993; Blumbergs et al., 1994; Sherriff et al., 
1994b; Blumbergs et al., 1995). TAI causes axonal transport impairments, which lead to 
accumulations of vesicles and organelles transported along axons. These accumulations 
result in reactive axonal swellings or retraction bulbs, leading to disconnection and 
degeneration (Povlishock and Christman, 1995). TAI can be detected within minutes to 
hours following injury in both humans and animal models using various 
immunohistochemical approaches. For instance, silver stain (Strich, 1956; 
Oppenheimer, 1968; Strich, 1970; Gennarelli et al., 1982), amyloid precursor protein 
(APP) and neurofilament immunohistochemistry (Yaghmai and Povlishock, 1992; 
Gentleman et al., 1993; Grady et al., 1993; Christman et al., 1994; Sherriff et al., 1994a; 
Graham et al., 1995; Povlishock and Christman, 1995; Chen et al., 1999; Stone et al., 
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2000, 2001; Marmarou et al., 2005) have all been used to document incidents of TAI. 
APP is transported along axons via the fast axonal transport machinery (Koo et al., 
1990). APP rapidly accumulates in retraction bulbs or varicosities following injury 
(Sherriff et al., 1994b; Graham et al., 1995; Stone et al., 2000; Marmarou et al., 2005). 
Neurofilament, on the other hand, makes up the axonal cytoskeleton. Increased 
neurofilament immunoreactivity is believed to result from misalignment and collapse of 
these structural proteins following injury (Erb and Povlishock, 1988; Yaghmai and 
Povlishock, 1992; Pettus et al., 1994). APP and neurofilament have since served as 
robust signatures of axonal injury. TAI can persist months to years following injury, 
although to a lesser extent than what being observed in the acute phase. Importantly, 
degree of TAI correlates with morbidity in humans and animal models and contributes 
to cognitive deficits (Adams, 1982; Gennarelli et al., 1982). 
Neuronal Cell Death and Atrophy 
Similar to axonal injury, neuronal and glial death has been documented at focal 
as well as diffuse locations throughout the brain following TBI (Povlishock and Katz, 
2005). Cell death at contusional, pericontusional, and distant sites triggered by TBI 
appears to involve both necrotic and apoptotic cascades (Raghupathi, 2004). Necrotic 
cell death is characterized by swollen neurons containing dilated mitochondria and 
pyknotic nuclei. Necrosis is associated with membrane failure and collapse of the 
cytoskeletal network. Meanwhile, apoptotic cell death is linked to double strand DNA 
breaks and nuclear condensation in the absence of membrane perturbation. Apoptosis 
has been hypothesized to be result from excitotoxicity, calcium dyshomeostasis, and 
deregulation of the apoptotic and anti-apoptotic pathways (Raghupathi, 2004). There is, 
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however, dissociation between cell death and morbidity/cognitive functions, as 
evidenced in humans and experimental TBI models (Strich, 1956; Lyeth et al., 1990; 
Laurer et al., 2001; DeFord et al., 2002). Furthermore, emerging evidence suggests that 
neuronal somata connected to injured axons often don’t die but atrophy over time 
(Singleton et al., 2002; Lifshitz et al., 2007).  
Inflammation 
Activation of astrocytes and microglia in response to TBI is evident within 
hours and persists for months post injury (Oppenheimer, 1968; Gennarelli et al., 1982; 
Geddes et al., 1997; Oehmichen et al., 1999; Hausmann et al., 2000). Activated 
astrocytes exhibit hypertrophic somata, while reactive microglia have reduced 
ramifications and ameboid-like morphologies. At the light microscopic level, astrocytes 
can be detected by staining with antibodies against glial fibrillary acidic protein (GFAP) 
and vimentin, both of which are intermediate filament proteins specific to astrocytes in 
the CNS (Smith et al., 1995; Dunn-Meynell and Levin, 1997; Hausmann et al., 2000; 
Chen et al., 2003). Microglia can be detected by antibodies against different cell surface 
receptors such as CD11b and CD68 (Oppenheimer, 1968; Soares et al., 1995; Geddes et 
al., 1997; Oehmichen et al., 1999; Chen et al., 2003; Kelley et al., 2007; Harting et al., 
2008), and by staining with Iba1 antibody, a calcium binding protein specific to 
microglia and macrophage (Sandhir et al., 2008; Shitaka et al., 2011). Both astrocytes 
and microglia are believed to have dual roles in the setting of TBI and various CNS 
injuries (Floyd and Lyeth, 2007; Loane and Byrnes, 2010). Depending on the time of 
activation, activated astrocytes and microglia can either contribute to secondary injury 
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or recovery following trauma. As such, this is an active area of research for TBI and 
various neurodegenerative diseases.  
1.1.3 Animal Models 
Several animal models have been developed to study the mechanisms of TBI. 
These range from non-human primates (Gennarelli et al., 1982; Maxwell et al., 1993), 
pigs (Smith et al., 1997; Raghupathi et al., 2004), sheep (Lewis et al., 1996; Van Den 
Heuvel et al., 2000; Grimmelt et al., 2011), cats (Povlishock and Becker, 1985; 
Christman et al., 1997), and small rodents such as rats and mice (Smith et al., 1991; 
Smith et al., 1995; Laurer et al., 2001; Longhi et al., 2005; Marmarou et al., 2005; Kelley 
et al., 2007; Lifshitz et al., 2007; Mac Donald et al., 2007a; Dikranian et al., 2008; 
Garman et al., 2011; Koliatsos et al., 2011; Shitaka et al., 2011). Several injury paradigms 
have also been tested to model different modes and aspects of injury severity spectrum. 
These include angular/rotational acceleration (Gennarelli et al., 1982; Smith et al., 1997), 
lateral fluid percussion (Smith et al., 1991; Hicks et al., 1993), weight drop (Foda and 
Marmarou, 1994), controlled cortical impact (Smith et al., 1995; Mac Donald et al., 
2007a), repetitive closed-skull impacts (Laurer et al., 2001; Raghupathi et al., 2004; 
Shitaka et al., 2011), and blast (Garman et al., 2011; Koliatsos et al., 2011). Although 
experimental TBI using primates and pigs closely recapitulate post TBI pathobiology in 
humans, these models face multiple ethical issues, are costly and not feasible for 
mechanistic studies. Therefore, experimental TBI models using rodents have been 
extensively utilized. Thus far, these models have proved useful in studying secondary 
injury mechanisms following injury. Notably, regardless of species or injury paradigms 
employed, TAI has been found as a universal consequence. 
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1.2 Alzheimer’s Disease 
1.2.1 Introduction 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly 
(Abbott, 2011). It is characterized by progressive cognitive, linguistic, and behavioral 
impairments and memory loss. Two core pathological hallmarks of AD are the 
extracellular plaques composed of the amyloid-beta (Aβ) peptides and the intracellular 
neurofibrillary tangles composed of the microtubule-associated protein tau. In addition 
to these two pathologies, progressive synaptic and neuronal loss and neuroinflammation 
are also prominent. Brain structures that are primarily damaged in AD are the limbic 
system and association cortices, which have important roles in memory and cognitive 
functions (Selkoe, 2001).  
AD can be classified into familial and sporadic forms. Familial AD accounts for 
less than 5%, while the rest of all the AD cases are sporadic.  Familial AD has an early 
age of onset, which ranges from 30 – 60 years of age. Sporadic AD typically starts in the 
60s. Apart from the age-of-onset difference, familial and sporadic AD cases share 
almost identical clinical and histopathological characteristics (Selkoe, 2001).  
Familial AD is inherited in an autosomal dominant fashion, and is caused by 
mutations in the APP (Chartier-Harlin et al., 1991; Crawford et al., 1991; Goate et al., 
1991), presenilin 1 (PS1) and presenilin 2 (PS2) genes (Levy-Lahad et al., 1995; Rogaev 
et al., 1995; Sherrington et al., 1995). APP is the precursor protein from which Aβ is 
derived (Kang et al., 1987); PS1 and PS2 proteins form part of the γ-secretase 
machinery that cleaves APP to generate Aβ (De Strooper et al., 1998). Virtually all 
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mutations in APP, PS1 and PS2 result in increase Aβ production, in particular the Aβ 
isoform which has 42 amino acids (Citron et al., 1992; Citron et al., 1994; Haass et al., 
1994; Lemere et al., 1996b; Mann et al., 1996; Scheuner et al., 1996; Citron et al., 1997). 
The only genetic factor proven to increase the risk of sporadic AD is the apolipoprotein 
E (ApoE) genotype (Saunders et al., 1993; Strittmatter et al., 1993): individuals inherited 
the ε4 allele of ApoE (ApoE4) have increased likelihood and decreased age-of-onset to 
AD development compared to individuals with ε3 (ApoE3) and ε2 alleles (ApoE2) 
(Corder et al., 1993). Presence of ApoE4 allele increases Aβ plaque load (Schmechel et 
al., 1993; Polvikoski et al., 1995; Tiraboschi et al., 2004), possibly by affecting Aβ 
clearance (Castellano et al., 2011). Together, these studies support the hypothesis that 
increases in Aβ generation and/or aggregation is central to AD pathogenesis.  
1.2.2 Amyloid beta (Aβ) 
Aβ peptide is the principal component of the extracellular plaques in AD 
(Masters et al., 1985). Sequential proteolytic cleavages of APP by β- and γ-secretases 
generate Aβ peptides that are typically 40 to 42 amino acids long. Once generated, Aβ 
can exist in monomeric state, or aggregate to form oligomers and fibrills. Aggregation of 
Aβ is concentration dependent, and occurs both intracellularly (Gouras et al., 2000; 
D'Andrea et al., 2001; Gyure et al., 2001; Mori et al., 2002a) and extracellularly (Muller-
Hill and Beyreuther, 1989; Lemere et al., 1996a; Selkoe, 2004; Finder and Glockshuber, 
2007). Mechanisms of toxicity of aggregated Aβ include: impaired axonal transport, 
impaired long-term potentiation, synaptic and spine loss, neuronal death, and ultimately 
leading to impairments in learning and memory (Chui et al., 1999; Wirths et al., 2001; 
Zhang et al., 2002; Oddo et al., 2003a; Casas et al., 2004; Shankar et al., 2007; Klyubin et 
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al., 2008; Shankar et al., 2008; Ittner et al., 2010; Vossel et al., 2010). Several lines of 
evidence support cerebral Aβ accumulation as an early and necessary step in AD 
pathogenesis. First, all patients with AD have abundance Aβ plaques (Dickson, 1997). 
Second, all mutations in familial AD invariably lead to increased Aβ production and 
aggregation (Selkoe, 2001). Third, Down’s patients who are trisomic for the APP gene 
have progressive Aβ buildup, followed by neurofibrillary tangle formations, and 
manifested clinical AD symptoms at an early age (Mann and Esiri, 1989; Iwatsubo et al., 
1995; Lemere et al., 1996a). As a consequence, most AD research and recent 
therapeutics have focused on reducing Aβ production and aggregation, or enhancing Aβ 
clearance (Carter et al., 2010; Blennow, 2011; Morgan, 2011). 
1.2.3 Tau 
The microtubule-associated protein tau is a major component of the 
neurofibrillary tangles (NFTs) found in AD, Pick’s disease, progressive supranuclear 
palsy, and frontal temporal dementias (FTDs), collectively known tauopathies. Tau is 
hyperphosphorylated and aggregates into straight or paired helical filaments in these 
diseases (Ballatore et al., 2007).  
Tau’s physiological function is to stabilize microtubule (Drechsel et al., 1992). 
Due to alternative splicing of a single tau gene, there are 6 major isoforms of tau 
expressed in the adult brain. These isoforms differ in the numbers of tubulin-binding 
repeats (either 3 or 4 repeats, and thus are known as 3R or 4R tau isoforms) and the 
absence or presence of one or two 29-amino acids inserts in the N-terminal domain of 
the protein (Goedert et al., 1989b; Goedert et al., 1989a). Expressions of these isoforms 
are tightly regulated, such that in the adult brain, 3R and 4R tau expression is 
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maintained at a one to one ratio. Deviation from this ratio can result in familial FTDs 
(Hong et al., 1998).  
Tau binding to microtubule is regulated by serine/threonine phosphorylation. 
Upregulation of activities of a number of kinases, such as cyclin-dependent kinase 5, 
glycogen synthase 3-β or downregulation of protein phosphatases have been proposed 
mechanisms underlying abnormal tau phosphorylation (Gong et al., 1993; Mazanetz and 
Fischer, 2007). Hyperphosphorylated tau has reduced microtubule binding capability, 
resulting in destabilized microtubules (Drechsel et al., 1992; Bramblett et al., 1993; 
Alonso et al., 1994; Merrick et al., 1997). This in turn compromises structural and 
functional integrity of the cytoskeleton, leading to axonal degeneration (Roy et al., 
2005). This is the basis of the hypothesis of how loss-of-function tau can promote 
neurodegeneration in tauopathies. Hyperphosphorylated tau can also gain toxic function 
such as sequestration of normal tau and other microtubule-associated proteins, further 
exacerbating the consequences of tau loss-of-function (Alonso et al., 1996; Alonso et al., 
1997; Guo and Lee, 2011).  
On the one hand, many studies suggest tau as a mediator of Aβ toxicity. For 
instance, tau knockout hippocampal neurons in culture were protected from 
degeneration induced by fibrillar Aβ (Rapoport et al., 2002). Further, axonal transport 
deficits induced by oligomeric Aβ were ameliorated by deletion of tau (Vossel et al., 
2010). In mouse models overexpressing human APP, tau deletion reduced behavioral 
deficits, excitoxicity and Aβ-induced cell death (Roberson et al., 2007; Ittner et al., 
2010). On the other hand, there is direct evidence to support the hypothesis that tau 
malfunction is sufficient to induce neurodegeneration in the absence of other 
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pathogenic insults. For instance, many mutations in the tau gene have been found to be 
causative of FTD with parkinsonism linked to chromosome-17 (FTDP-17) (Goedert 
and Jakes, 2005). Consequently, targeting tau either by reducing its phosphorylation 
state or aggregation may prove useful in the setting of AD and related dementias. This 
has gotten more attention in recent years (Brunden et al., 2009; Ballatore et al., 2010; 
Brunden et al., 2010a).  
1.3 Link between TBI and AD 
Several lines of evidence link TBI and subsequent development of AD. First, 
many epidemiological studies demonstrate that a history of head trauma substantially 
increases the risk of dementia of the AD type (Mortimer et al., 1991; Plassman et al., 
2000; Fleminger et al., 2003). Second, both intracellular and extracellular accumulations 
of Aβ have been documented in approximately 30% of cases with severe TBI, but less 
frequently following mild, concussive TBI (Roberts et al., 1990; Roberts et al., 1991; 
Tokuda et al., 1991; Smith et al., 2003c; Ikonomovic et al., 2004; Uryu et al., 2007; 
Johnson et al., 2011). Notably, Aβ accumulations could occur within hours to days 
following injury in young individuals who do not have a preexisting history of 
neurodegeneration. Third, NFTs containing hyperphosphorylated tau are prominent 
pathological features in the brain of boxers and athletes with a lifelong history of 
concussions, resulting in a condition known as dementia pugilistica or chronic traumatic 
encephalopathy (Roberts et al., 1990; Schmidt et al., 2001; McKee et al., 2009). Severe 
TBI has also been reported to cause acute accumulations of total and phosphorylated 
tau in injured axons (Ikonomovic et al., 2004; Uryu et al., 2007), and NFTs years 
   11 
 
following injury (Johnson et al., 2011). Fourth, individuals with TBI who are ApoE4 
carriers are at greater risk of AD (Mayeux et al., 1995; Katzman et al., 1996). Further, 
ApoE4 genotype is associated with poorer outcome following TBI (Sorbi et al., 1995; 
Teasdale et al., 1997; Friedman et al., 1999; Lichtman et al., 2000; Diaz-Arrastia et al., 
2003; Teasdale et al., 2005; Zhou et al., 2008), possibly by acting via exacerbation of Aβ 
and tau accumulation (Verghese et al., 2011). Together, these findings support the 
hypothesis that TBI is causally linked to AD.  
This hypothesis was supported by findings in rotational head injury using pigs: 
within days following injury, diffuse Aβ plaques, axonal Aβ and tau accumulation, as 
well as NFTs were documented (Smith et al., 1999b). However, it is difficult to perform 
mechanistic studies using pigs. Therefore, a number of groups have attempted to model 
these pathologies by subjecting small rodents to various experimental TBI paradigms. 
For instance, experimental TBI in the rats have been reported to cause intra-axonal Aβ 
accumulations within hours post injury (Stone et al., 2002); this pathology could persist 
up to a year (Iwata et al., 2002). While Smith et al. reported that controlled cortical 
impact TBI (CCI) in transgenic mice overexpressing mutant APP (PDAPP) resulted in 
an increase in tissue Aβ levels at 2 hours post injury (Smith et al., 1998), our lab 
observed the contrary (Schwetye et al., 2010). Further, Nakagawa et al. observed 
regression of Aβ plaques in PDAPP mice months following CCI (Nakagawa et al., 1999; 
Nakagawa et al., 2000). Meanwhile, Hartman et al. reported that CCI accelerated Aβ 
plaque formation in PDAPP and ApoE4 double transgenic mice (Hartman et al., 2002). 
Uryu et al. demonstrated that multiple closed-skull impacts accelerated Aβ plaque load 
at 16 weeks post injury in Tg2576 mice, another transgenic APP line (Uryu et al., 2002). 
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However, using a similar repetitive impact model, Yoshiyama et al. observed accelerated 
NFTs formation in only 1 of 12 injured tau transgenic mice (Yoshiyama et al., 2005). 
These models have not only reported mixed findings on TBI and AD interaction, but 
also have fallen short of reproducing both the Aβ and tau pathological features 
observed in humans. Furthermore, they did not allow assessment of the interaction 
between human Aβ and tau in the setting of brain trauma. Consequently, prior to this 
work, the field as a whole was in need of an appropriate small animal TBI model to 
investigate the pathomechanisms linking TBI and AD. 
1.4 Summary 
To summarize, TBI and AD are important public health issues. There exists an 
unequivocal link between them. However, mechanisms linking TBI and AD remain 
incompletely understood in part because of the lack of an appropriate small animal 
model. Therefore, the goals of my thesis were to 1) develop a mouse TBI model that 
more closely resembled post-traumatic pathologies in human, 2) use the model to 
understand the interaction between Aβ and tau in the setting of trauma, 3) determine 
the mechanisms underlying tau pathology following injury, and 4) investigate the long-
term behavioral and neurodegenerative consequences of the acute Aβ and tau 
pathologies observed post injury. 
 
   13 
 
Chapter 2 
Experimental Designs and Methods 
2.1 Animals 
We utilized 5-7 month old homozygous 3xTg-AD mice (Oddo et al., 2003b) of 
both sexes on B6/SJV129 background in all experiments. 3xTg-AD mice were 
generated by microinjection of the APPswe and TauP301L transgene constructs, both under 
the control of the mouse Thy1.2 promoter, into single-cell embryos of mutant 
homozygous PS1M146V knockin mice (Guo et al., 1999). These 3xTg-AD mice breed as 
readily as a “single” transgenic line because the APPswe and TauP301L transgene cassettes 
cosegregated, and the M146V mutation was “knocked in” to the endogenous mouse 
PS1 locus. 3xTg-AD mice used in most experiments were derived from founders 
received from the LaFerla lab in 2007, unless otherwise noted. Aβ and tau pathologies 
have been stable since that time, with no evidence of drift.  
We also used 2 month old heterozygous APPswe/PSEN1ΔE9 (APP/PS1) 
transgenic mice (line 85, Stock number 004462, The Jackson Laboratory). APP/PS1 
mice overexpress human APP swedish gene and human PSEN1 with an exon 9 deletion 
(Jankowsky et al., 2004).  
We also used 6 month old heterozygous TauP301L mice.  TauP301L mice 
overexpress human tau gene with P301L mutation (Gotz et al., 2001) under the Thy1 
promoter. 
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 For behavioral assessment in the Morris water maze, we crossed 3xTg-AD mice 
to homozygous PS1M146V mice, the line from which the original 3xTg-AD line was 
derived from. These PS1M146V mice were received from the Mattson lab in 2009 (Guo et 
al., 1999). Since differences in genetic background strains may influence behavioral 
performance (Owen et al., 1997; Holmes et al., 2002), we generated homozygous 3xTg-
AD mice and PS1M146V littermates and used them for behavioral assessment. The 
following breeding scheme was employed. First, homozygous 3xTg-AD mice were 
crossed to homozygous PS1M146V to generate offspring that were heterozygous in human 
APPswe and TauP301L genes and homozygous in PS1M146V (APP+/-Tau+/-PS1+/+). Non-
sibling APP+/- Tau+/- PS1+/+ mice were then crossed to generate mice which had the 
following genotypes with expected Mendelian ratios: APP+/+ Tau+/+ PS1+/+ (denoted 
3xTg), APP+/- Tau+/- PS1+/+, and APP-/- Tau-/- PS1+/+ (denoted PS1). APP+/-Tau+/-PS1+/+ 
heterozygous mice were not used in any of the experiments. 
Mice were housed in standard cages in 12 h light, 12 h dark cycle and given food 
and water ad. lib. Mice of both sexes were randomly assigned to experimental groups. 
All experiments were approved by the animal studies committee at Washington 
University in St Louis. 
2.3 Genotyping 
Genotyping of 3xTg-AD, TauP301L, and APP/PS1 mice were done as previously 
described (Gotz et al., 2001; Oddo et al., 2003b; Jankowsky et al., 2004). 
A real-time PCR comparative CT method was developed to discriminate 
between 3xTg homozygous and heterozygous mice generated in our lab.  Using 
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sequence derived from the transgene cassette, primers for APP, Tau and endogenous β-
actin were generated using Primer Express 3.0 software (Applied Biosystems (ABI), 
Carlsbad, California): β-actin-sense (AGTGTGACGTTGACATCCGTA),   β-actin-
antisense (GCCAGAGCAGTAATCTCCTTCT), APP-sense 
(AAACCGGGCAGCATCGA), APP-antisense 
(GGAACTCTTGGCACCTAGAGGAT), Tau-sense (GGTGGGTGGCGGTGACT), 
Tau-antisense (TAGCTTTCCCCACCACAGAATC).   
For genotyping, 1–2 mm sections of tail biopsy were processed using the 
DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) to isolate genomic DNA.  PCR 
analysis was performed using an Applied Biosystems 7500 Fast Real-Time PCR system 
with Syber Green PCR Master Mix (ABI).  The delta-CT between the β-actin gene and 
APP or Tau was measured against known homozygote and heterozygote animals and 
found to be stable and able to clearly distinguish unknown genotypes. Genotyping of 
PS1M146V transgene expression was done as previously described (Guo et al., 1999). 
2.4 Controlled Cortical Impact Experimental 
TBI 
The experimental TBI methods used in this study were performed as described 
previously (Brody et al., 2007; Mac Donald et al., 2007b). Briefly, mice were 
anesthetized with isoflurane (5% induction, 2% maintenance) and placed on a 
stereotaxic frame. After midline skin incision, a 5 mm left lateral craniotomy was made 
using a motorized drill. Controlled cortical impact was produced with an 
electromagnetic impact device using a 3 mm diameter metal tip. The impact was 
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centered at 2.7 mm lateral to midline and 3.0 mm anterior to lambda. Injury severities of 
1.0 mm, 1.5 mm, and 2.0 mm below the dura were chosen to model mild, mild-
moderate, and moderate injuries, respectively. After injury, the impact site was covered 
with a plastic skull cap, skin was sutured, and mice were allowed to recover on a heated 
pad. Mice were kept at 37 ˚C via a rectal temperature probe and feedback temperature 
controller throughout the duration of the surgery (Cell MicroControls). Temperature 
control is important because hypothermia alone has been reported to cause tau 
accumulation and hyperphosphorylation (Planel et al., 2004). Sham mice underwent the 
same surgical procedure including anesthesia and craniotomy but were not injured.   
2.5 Antibodies 
Antibodies used are listed in Table 2.1.To avoid using anti-mouse secondary 
antibodies on injured tissues, most monoclonal antibodies were conjugated to biotin or 
directly labeled. 3D6 and HJ3.4 was biotinylated with NHS-LC-biotin from Pierce. 
Conjugation of 3D6 to Alexa Fluor® 596 was done via commercially available kit 
(A20185, Invitrogen Corp).  
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Table 2.1 List of antibodies used in all experiments 
 
Protein Antibody Epitope Host/Application 
Dilution 
Source/Cat # 
Aβ 
  
3D6 aa1-5 requiring 
free N terminus.  
Mouse/IHC, ELISA 
1 µg/ml 
Eli Lilly and Co 
 m266 aa13-28 Mouse/ELISA 
10 µg/ml 
Eli Lilly and Co 
 2G3 aa35-40 Mouse/ELISA 
20 µg/ml 
Eli Lilly and Co 
  21F12 aa33-42 Mouse/ELISA 
20 µg/ml 
Eli Lilly and Co 
 HJ3.4 aa1-13 Mouse/IHC 
0.75 µg/ml 
Dr. David 
Holtzman 
  panAβ aa15-30 Rabbit/IHC 
0.8 µg/ml 
Invitrogen 
(44-136) 
  Aβ40 aa34-40 Rabbit/IHC 
0.5 µg/ml 
Invitrogen 
(44-348A) 
  Aβ42 aa36-42 Rabbit/IHC 
5 µg/ml 
Chemicon 
(AB5078P) 
 82E1 requires free N-
terminus 
Mouse/IP 
10 µg 
IBL-America 
10323 
APP APP full-length, C-
terminal 
Rabbit/IHC, WB 
0.5 µg/ml 
Invitrogen 
(51-2700) 
 6E10 Aβ/APP Mouse/IP (10 
µg)/WB (1 µg/ml) 
Covance 
SIG-39300 
Tau HT7 panTau Mouse/IHC 
0.2 µg/ml 
Pierce 
(MN1000) 
 pAb Tau panTau Sheep/IHC 
1 µg/ml 
Pierce 
(PN1000) 
 Tau46 panTau Mouse/WB 
1:1000 
Cell Signaling 
(4109) 
 AT8 pS199, pS202, 
pT205 
Mouse/WB 
1:1000 
Pierce 
(MN1020) 
 AT100 pS212, pT214 Mouse/WB 
1:1000 
Pierce 
(MN1060) 
 AT180 pT231 Mouse/WB 
1:1000 
Autogen 
Bioclear (90218) 
 S199 pS199 Rabbit/IHC 
1:2000 
Invitrogen 
(44734G) 
 T205 pT205 Rabbit/IHC 
1:1000 
Invitrogen 
(44738G) 
 T231 pT231 Rabbit/IHC  
1:1000 
Invitrogen 
(44746G) 
 S396 pS396 Rabbit/IHC 
1:1000 
Invitrogen 
(44751G) 
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 S422 pS422 Rabbit/IHC 
1:1000 
Invitrogen 
(44764G) 
 PHF1 pS396/pS404 Mouse/IHC 
1:500 
Dr. Peter Davies 
 
Neurofilament NF-L NF-L 68kD Mouse/IHC 
0.5 µg/ml 
Sigma 
(N5139) 
Tubulin Tubulin α-tubulin Mouse/WB 
1 µg/ml 
Sigma 
(T5168) 
PKA PKA α and β catalytic 
subunits 
Goat/WB 
0.4 µg/ml 
Santa Cruz 
Biotechnology  
(sc-30668) 
 p-PKA pT198 of α and 
β catalytic 
subunits 
Rabbit/WB, IHC 
0.4 µg/ml 
Santa Cruz 
Biotechnology 
(sc-32968) 
ERK1/2 p44/42 
MAPK 
full length, C-
terminus 
Rabbit/WB 
1:500 
Cell Signaling 
(4695) 
 p-p44/42 
MAPK 
pT202 and 
pY204 
Rabbit/WB, IHC 
1:500 
Cell Signaling 
(4370) 
GSK3β GSK3β full length Rabbit/WB 
1:1000 
Cell Signaling 
(9315) 
 p-GSK3β pS9  Rabbit/WB, IHC 
1:500 
Cell Signaling 
(#9323) 
 p-GSK3 pY279 of α and 
pY216 of β 
subunits 
Rabbit/IHC 
1:500 
Invitrogen 
(44604G) 
JNK JNK full length Rabbit/WB 
1:1000 
Cell Signaling 
(9258) 
 p-JNK pT183 and 
pY185 
Rabbit/WB, IHC 
1:500 
Cell Signaling 
(4668) 
CDK5 CDK5 full length Rabbit/WB, IHC 
1:500 
Cell Signaling 
(2506) 
p35/25 p35/25 full length, C-
terminus 
Rabbit/WB 
1:1000 
Cell Signaling 
(2680) 
c-jun p-c-jun pS63 Rabbit/IHC 
1:500 
Cell Signaling 
(2361) 
IHC: immunohistochemistry; ELISA: enzyme-linked immuno absorbant assay; IP: 
immunoprecipitation; WB: western blot; p: phosphorylated. 
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2.6 Histology 
2.6.1 Immunohistochemistry 
Animals were sacrificed via deep isofluorane anesthesia, followed by 
transcardiac perfusion using ice-cold phosphate buffered saline (PBS) and 0.3 % 
heparin. Brains were removed and fixed in 4% paraformaldehyde for 24 h. Brains were 
subsequently cryoprotected and equilibrated in PBS solution containing 30% sucrose 
for 2 days. A sliding microtome was used to generate coronal 50 µm sections. All 
immunohistochemical studies were done on free-floating sections. All sections were 
washed with tris-buffered saline (TBS) between applications of antibody solutions. 
Antigen retrieval with 70% formic acid (3-5 minutes) was performed for Aβ and 
phospho-tau staining. Non-specific binding was blocked by incubation in TBS 
containing 0.25% Triton X (TBS-X) and 3% nonfat dry milk (monoclonal anti-Aβ 
antibodies) or 3% serum (monoclonal anti-tau and polyclonal antibodies) or 5% BSA 
(phospho-tau antibodies). Primary antibody was diluted in 1% nonfat dry milk, 1% 
serum or 1% BSA in TBS-X. Table 2.1 listed of all antibodies used. Bound antibodies 
were detected with biotinylated secondary antibodies, except for 3D6 and HJ3.4, which 
were directly biotinylated. Horse-radish peroxidase method (ABC Elite kit, PK6100, 
Vector Laboratories) and DAB were utilized for visualization of bound antibodies. 
To reduce background staining on injured tissues when staining with 
monoclonal NF-L and  PHF1 antibodies, an additional blocking step for 1 hour with 
unconjugated anti-mouse monovalent Fab fragments (Jackson ImmunoResearch, 315-
007-003, 130 µg/ml) was performed following blocking with serum.  
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Following color development with DAB, sections were mounted on glass slides, 
dried for at least 1 h, and then differentiated through a series of 50%, 70%, 90%, 100%, 
and 100% ethanol; 1 minute each. Slides were cleared in Xylene 2 times, for 4 minutes 
each. Slides were cover slipped in Cytoseal 60 resinous medium (Thermo Scientific, 
8310), and allowed to dry overnight before quantification or photomicroscopy. 
2.6.2 Double Immunofluorescence  
In double labeling studies, primary antibodies were sequentially applied, 
followed by Alexa Fluor® conjugated secondary antibodies except for 3D6, which was 
conjugated to Alexa Fluor® 596. 
For double labeling of phospho-tau and activated JNK (phospho-JNK, p-JNK), 
sections were first incubated with rabbit anti-pS199, followed by goat anti-rabbit 
secondary antibody conjugated to Alexa Fluor® 488 (Invitrogen, A11008, 2 µg/ml). 
Sections were blocked again for 30 minutes with 3% normal rabbit serum to saturate 
open binding sites on the first secondary antibody with IgG. Sections were then 
incubated for 1 hour in excess of unconjugated goat anti-rabbit monovalent Fab 
fragments (Jackson ImmunoResearch, 111-007-003, 130 µg/ml). This was done to 
cover the rabbit IgG so that the second secondary antibody would not bind to it. Rabbit 
anti-p-JNK was subsequently applied, followed by goat anti-rabbit conjugated to Alexa 
Fluor® 594 (Invitrogen, A11012, 2 µg/ml). Sections were washed with TBS 3 times for 
5 minutes each between steps. Sections were mounted and cover slipped using 
VectaShield mounting medium (Vector Laboratories, H-1000). Images were obtained 
using LSM 5 Pascal software (Zeiss Physiology Software) coupled to an LSM Pascal 
Vario 2RGB confocal system (Zeiss).  
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2.6.3 Cresyl Violet Staining 
Cresyl violet staining was used for delineation of cytoarchitecture. Sections were 
mounted on glass slides. After drying, slides were incubated for 2 min in 0.25 % cresyl 
violet solution (pH 3.5), rinsed in distill water, and differentiated in series of 50%, 70%, 
95%, 100% and 100% ethanol; 1 minute each. Slides were cleared in Xylene 2 times, for 
4 minutes each. Slides were cover slipped in Cytoseal 60 resinous medium (Thermo 
Scientific, 8310), and allowed to dry overnight before quantification or or 
photomicroscopy. 
2.6.3 X-34 Staining 
For detection of fibrillar structures, X-34 staining was performed. Mounted sections 
were first permeabilized with 0.25% Triton-X phosphate buffered saline (PBS) for 30 
minutes. Slides were then incubated in 10 µM X-34 staining solution containing 40% 
ethanol, 60% PBS, and 0.02 N sodium hydroxide. After rinsing 3 times in 40% ethanol 
and 60% PBS buffer, for 5 minutes each, slides were cover slipped with VectaShield 
mounting medium (Vector Laboratories, H-1000). 
2.7 Biochemical Assessments 
2.7.1 Preparation of Tissues Homogenates for Aβ 
Detection by Human-Specific ELISAs 
Separate groups of sham and TBI (2.0 mm) mice were sacrificed at 24 h post 
surgery; hippocampi ipsilateral and contralateral to impact site (including fimbria and 
surrounding white matter tracts) were dounce homogenized in 1:10 w/v of TBS. 
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Supernatants were kept and pellets were subsequently sonicated in a 1:5 w/v solution of 
100 mM sodium carbonate, pH 11, containing 50 mM sodium chloride (Carbonate 
lysates). Finally, remaining pellets were homogenized in 1:5 w/v 5M Guanidine-
hydrochloride, rotated at room temperature for 3-4 h (Guan lysates). All buffers used 
for homogenization contained protease and phosphatase inhibitor cocktails (Roche). 
Supernatants and pellets from all tissue suspensions were obtained by spinning at 13,300 
g for 20 minutes at 4˚C. Protein concentrations were determined via BCA method 
(Pierce Biotech, Inc.). TBS, Carbonate, and Guanidine lysates prepared above were 
tested for Aβ contents using a human specific Aβ ELISA, as described (Cirrito et al., 
2003; Kang et al., 2007). Capture antibodies were m266 for the total Aβ1-x ELISA, 2G3 
for the Aβ1-40 ELISA, and 21F12 for the Aβ1-42 ELISA. Detection antibody was 3D6-
biotin. These antibodies were gifts from Eli Lilly and Co. 
2.7.2 Preparation of Tissue Homogenates for APP 
Western Blots 
Bilateral cerebellar tissue was homogenized in modified RIPA buffer containing 
protease inhibitor cocktails (Roche), as described (Cirrito et al., 2003). Protein 
concentrations were determined via BCA method (Pierce Biotech, Inc.). Equal amounts 
of samples were electrophoresed on 4-12% Bis-Tris NuPAGE gels using MES buffer 
(Invitrogen Corp) and transferred to 0.2 μm pore nitrocellulose membrane. After 
transfer, membranes were blocked in 3% non-fat dry milk in 50 mM Tris, pH 7.6 buffer 
containing 150 mM NaCl and 0.1% Tween 20 (TBS-T) for 1 h at room temperature. 
After washing in TBS-T three times, 5 minutes each, membranes were incubated with 
polyclonal APP antibody (0.25 µg/ml) in blocking buffer overnight at 4 ˚C. Bound 
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antibodies were detected with HRP-conjugated donkey-α-rabbit IgG (GE Healthcare, at 
1:10,000) and the ECL Advance Western Blotting detection kit (GE Healthcare). Blots 
were stripped and reprobed with anti-α-tubulin (1 µg/ml) for loading control. Images 
were taken on film and scanned.  
2.7.3 Preparation of Tissue Homogenates for Tau Western 
Blotting and ELISAs 
Separate groups of and injured (2.0 mm) 3xTg-AD mice were sacrificed at 24 h 
by rapid decapitation. Bilateral hippocampi were dissected, immediately frozen, and 
stored at -80°C. Frozen hippocampi were homogenized in modified RIPA buffer 
containing protease and phosphatase inhibitor cocktails (Roche), as described (Cirrito et 
al., 2003). Homogenates were centrifuged at 13,000 rpm for 20 minutes at 4 ˚C. After 
pre-clearing samples with protein G sepharose beads to remove endogenous mouse 
IgG, protein concentrations were determined using the BCA method (Pierce). Equal 
amounts of samples were electrophoresed on 10% BisTris NUPAGE gels (Invitrogen 
Corp). After transfer, 0.2 µm pore nitrocellulose membranes were blocked with 5% 
non-fat dry milk TBS-T for 1 h, and probed with AT8 (1:1000), AT100 (1:1000), or 
AT180 (1:1000) in 5% BSA TBS-T overnight at 4°C. Sheep-α-mouse HRP (GE 
Healthcare, 1:12,000) and ECL Advance Western Blotting kit (GE Healthcare) were 
used to detect bound antibodies. Blots were stripped and reprobed for total tau using 
Tau46 antibody (1:1000). Blots were scanned and densitometry was performed via 
Image J (NIH). Total and phospho-S199 tau ELISAs were performed per 
manufacturer’s instructions (Invitrogen Corp). 
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2.7.4 Western Blotting of Tau Kinases 
The RIPA homogenates from ipsilateral hippocampi prepared for tau western 
blots and ELISAs were used to assess total and activated levels of several tau kinases. 
Equal amounts of each sample (6 µg) were electrophoresed on 10% BisTris NUPAGE 
gels using MOPS buffer (Invitrogen). Gels were transferred to 0.2 µm nitrocellulose 
membranes, which were then blocked with tris buffered saline containing 0.1% Tween-
20 (TBS-T) and 5% non-fat dry milk for 1 h at room temperature. Membranes were 
incubated overnight in TBS-T buffer containing 5% BSA and the appropriate primary 
antibodies. Corresponding anti-rabbit-HRP (GE Healthcare, 1:10,000) or anti-goat-
HRP (Invitrogen, 1:10,000) and ECL Advance Western Blotting kit (GE Healthcare) 
were used for detection. Blots were washed 4 times for 5 minutes each with TBS-T 
between blocking and applications of antibodies. Blots were scanned, and densitometry 
was performed via Image J (NIH). 
2.7.5 Immunoprecipitation and Western Blot to 
demonstrate specificity of HJ3.4 antibody toward Aβ, 
not APP 
To verify the specificity of HJ3.4 for Aβ over amyloid precursor protein (APP), 
an immunodepletion assay was performed on brain homogenate from a 9 month old 
3xTg-AD mouse.  Whole brain was removed after transcardial perfusion with PBS 
containing 0.3% heparin and immediately dounce homogenized in RIPA buffer (150 
mM NaCl, 50 mM Tris-HCl, 1% Triton X-100, 0.10% SDS, 0.5% deoxycholic acid, 2.5 
mM EDTA, pH 8.0) containing protease inhibitor cocktail (Roche) at a 10:1 ratio 
(RIPA volume/tissue weight) using 25 strokes followed by brief sonication.  The 
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resulting homogenate was centrifuged for 20 minutes at 17,000xg at 4°C to remove 
insoluble protein.  Total protein was determined using a standard BCA protein assay.  
Individual aliquots containing 100 μg of homogenate were immunodepleted using 10 μg 
of each antibody (HJ3.4, 82E1, 6E10). After overnight incubation, complexes were 
captured using 150 μg Protein-G Dynabeads® (#100.03D, Invitrogen).  The resulting 
immunodepleted supernatants were assayed by Western blot, as described below, to 
determine affinity in solution for APP. 
 Samples for Western blot analysis were combined with standard Laemmli buffer 
and heated to 85°C to denature for 5 minutes.  Protein samples were size separated on 
NuPAGE® 12% Bis-Tris gels (Invitrogen) in 2-(N-morpholino)ethanesulfonic acid 
(MES) SDS running buffer at 150 Volts.  SeeBlue® Plus-2 prestained standard 
(Invitrogen) was used to visualize and estimate the progression and size of the sample 
migration.  Gels were then transferred to 0.2 μm nitrocellulose using Towbin buffer (25 
mM Tris, 192 mM glycine, pH 8.6) containing 20% methanol at 150 mA for 1 hour.  
For Aβ western blotting, membranes were incubated at 95°C for 1 minute in PBS to 
allow for improved antigen binding and then cooled in room temperature PBS prior to 
blocking.  Membranes were blocked in 2% non-fat dry milk (NFDM) PBS for 1 hour.  
Between all remaining steps, membranes were washed 3x for 10 minutes each with PBS-
T (0.05% Tween 20).  For detection of APP, the mouse monoclonal 6E10 was used at 1 
μg/mL in 2% NFDM PBS overnight at 4°C.  Bound primary antibodies were detected 
using a sheep anti-mouse-HRP (#NA931V, GE Healthcare) at 50 ng/mL in 2% 
NFDM PBS and then developed with ECL Advance Reagent (GE Healthcare) followed 
by exposure to film emulsion. 
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2.7.6 Protein Phosphatase Activity Assays 
Serine/threonine phosphatase activity assay kits (V2460) were purchased from 
Promega Corp. Assays were performed on a 96-well plate format, per manufacturer’s 
instructions. Briefly, to remove phosphatase inhibitors and endogenous phosphates 
from RIPA hippocampal lysates, samples were desalted using the Zeba micro spin 
desalting columns (Pierce, 89877). Each sample was run in duplicate reactions; each 
contained 2 µl of lysates, 10 µl of appropriate 5x phosphatase reaction buffer, 5 µl of 1 
mM phosphopeptide, and 33 µl of deionized H2O. Protein phosphatase 2A (PP2A) 
reaction buffer contained 250 mM imidazole, 1mM EGTA, 0.1% β-mercaptoethanol, 
and 0.5 mg/ml acetylated BSA (Promega, R3961). In addition to the reagents listed for 
PP2A reaction buffer, PP2B (calcineurin) reaction buffer also included 50 mM MgCl2, 5 
mM NiCl2, 250 µg/ml calmodulin (Calbiochem, 208690). Plates were incubated at 30 ˚C 
for 30 minutes for phosphatase reactions to take place. Reactions were stopped by 
addition of 50 µl of Molybdate Dye/Additive mixture to each well. Plates were 
subsequently incubated at room temperature for 30 minutes to allow the Molybdate 
Dye to bind to free phosphates released from the reaction. Plates were read using a 
plate reader with 630 nm filter. Optical densities of the samples were determined based 
on the optical densities of free phosphate standards. Specific activities for PP2A and 
PP2B were expressed as pmol phosphates per minute per µg of total protein.  
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2.8 Drug Treatment 
2.8.1 γ-secretase Inhibition with Compound E to Block Aβ 
Production 
To prevent post-traumatic intra-axonal Aβ accumulation, mice were treated with 
intraperitoneal (i.p.) injections of vehicle or Compound E, a small molecule inhibitor of 
γ-secretase (10 mg/kg; Axxora) (Seiffert et al., 2000; Olson et al., 2001; Grimwood et al., 
2005; Yang et al., 2008; Yan et al., 2009). One group of mice received Compound E 
(CmpE) or 0.8% DMSO vehicle starting at 1 h before injury, then again at 5 h, 11 h, 
and 17 h post injury. These mice were sacrificed 24 h after injury. Another group of 
mice received 4 CmpE or vehicle injections in the first 24 hours as noted above 
followed by injections twice daily until 7 days post injury. 10 mg/kg of Compound E 
was used because this dose has been shown to inhibit cortical γ-secretase activity in 
guinea pigs by 71 ± 4%, measured ex vivo (Grimwood et al., 2005). Furthermore, the 
frequent dosing regimen was employed due to the short half-life of Compound E: ~5-6 
hours (Yan et al., 2009). Lastly, this relatively high dose was also chosen because of the 
presence of the presenilin1 (PS1M146L) mutation in 3xTg-AD mice, as PS1 mutations 
have been shown to have diminished response to γ-secretase inhibition (Czirr et al., 
2007). Mice tolerated these dosing regimens well without additional weight-loss, lethargy 
or unexpected mortality.  
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2.8.2 Inhibition of c-jun N-terminal Kinase (JNK) by 
peptide inhibitor, D-JNKi1 
D-JNKi1 peptide (BML-EI355) and D-TAT control peptide (BML-EI384) were 
purchased from Enzo Life Sciences International, Inc. D-JNKi1 peptide is a specific 
inhibitor of JNK, which blocks the interaction between JNK (JNK-1, -2, -3) and its 
substrates (Bonny et al., 2001; Barr et al., 2002; Borsello et al., 2003b; Borsello et al., 
2003a). D-JNKi1 is cell permeable and has longer half life than its L-stereoisomer. D-
JNKi1 contains a 20-amino acid sequence of the JNK binding domain of the JNK-
interaction protein JIP1 covalently linked to the 10-amino acid HIV-TAT sequence. D-
TAT control peptide contains only the 10-amino acid HIV-TAT sequence. Prior to 
craniotomy and TBI induction, a 1 mm burr hole was drilled on the right hemisphere, at 
-0.5 mm posterior to bregma and 1.0 mm lateral to midline. Mice were randomly 
assigned to receive either D-JNKi1 or D-TAT (solublized in 0.1% DMSO PBS, 5 µg in 
5 µl) immediately post injury at 0.3 µl/min rate. A 33 gauge needle attached to a 
Hamilton syringe and KDS310 nano pump system (KDS Scientific Inc) was lowered -
2.2 mm below the dura through the burr hole to deliver peptide solutions (5 µl in total 
volume) into the right lateral ventricle. Mice recovered well after the combined injury 
and intracerebralventricular (i.c.v.) injection procedure. They lost approximately 10% of 
their original body weight, which was similar to mice that underwent only TBI 
procedure. 
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2.9 Quantitative Analyses of Histological 
Data 
2.9.1 Stereology 
Stereological methods were available via StereoInvestigator version 8.2 software. 
All assessments were made by investigators who were blinded to injury status, time 
sacrificed post injury, and treatment regimens of experimental animals. The optical 
fractionator method was employed for quantification of total numbers of markers of 
interest per cubic mm of tissue. Details on this stereological method have been 
described (Mac Donald et al., 2007b). Briefly, for quantification of HJ3.4, Aβ40-positive 
axonal varicosities in ipsilateral fimbria and tau-positive somata in ipsilateral amygdala, a 
200 µm x 200 µm sampling grid and a 75 µm x 75 µm counting frame were used. For 
quantification of total tau, APP and panAβ-positive puncta in ipsilateral fimbria, a 300 
µm x 300 µm grid and a 40 µm x 40 µm counting frame were employed. For pS199-, 
and PHF1-positive puncta in the fimbria, a 200 µm x 200 µm grid and a 50 µm x 50 µm 
counting frame was used. Dissector height of 15 µm and guard zones of 2.5 µm were 
employed for all measurements.  Four sections per mouse, each separated by 300 µm, 
were used for these estimations. These sections spanned approximately bregma -1.06 to 
-1.96 mm (Franklin and Paxinos, 1997). The spherical probe (aka ‘space balls’) method 
was used for quantification of the total length of tau immunoreactive processes in the 
dorsal contralateral CA1 region (Mouton et al., 2002). A sampling grid of 250 µm x 250 
µm and a hemispherical probe with 17 µm radius were employed. Three sections per 
mouse from approximately bregma -1.46 to -2.06 mm were used for this quantification.  
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Stereological quantifications of D-JNKi1 and D-TAT treated mice were 
according to the aforementioned methods, except that each brain sections were 
separated by 400 µm. 
2.9.2 Densitometry 
Densitometric analysis of kinase IHC was performed on the ipsilateral 
fimbria/fornix of 4 sections per mouse; each section separated by 400 µm. Phospho-c-
jun IHC quantification was performed on the ipsilateral thalamus using 5 sections per 
mouse. These sections spanned approximately bregma -0.8 mm to -2.6 mm. Slides were 
scanned using a Nanozoomer HT system (Hamamatsu Photonics) to obtain digitized 
images. Images were converted to 8-bit, thresholded, and percentage areas occupied by 
each kinase and p-c-jun stains were quantified using the Image J software (National 
Institutes of Health).  
2.9.3 Estimations of Hippocampus and Fimbria Volume 
Estimations were done on cresyl violet stained sections. Seven to eight sections 
per mouse, spanned approximately from bregma -0.94 mm to -3.1 mm were used for 
hippocampal volume estimation, while five to six sections were used for fimbria. Each 
section is separated by 300 µm. Images were digitally captured using the Nanozoomer 
HT system (Hamamatsu Photonics). Images were loaded into the ImageJ software 
(National Institute of Health). Areas of the hippocampus and fimbria were estimated 
based on the drawn contours around these regions via the polygon tools in ImageJ. 
Hippocampus and fimbria volume were calculated by multiplying total area to spacing 
between sections (300 µm), based on the Cavalieri principle. 
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2.10 Morris Water Maze 
3xTg and PS1 littermates were randomly assigned to TBI or sham groups and 
tested on the Morris water maze at either 1 month or 6 months following TBI or sham 
surgeries. Investigator was blinded to genotypes and injury status of the mice. Detailed 
descriptions of the test were as previously described (Brody et al., 2007). Briefly, the 
circular pool was 109 cm in diameter; the platform was 11 cm in diameter. The water 
was opacified using non-toxic white paint. Each mouse was given 60 seconds to swim 
to find a visible platform above the water surface, marked with a pole. Training was 
repeated 4 times per day for 3 days. Then, mice were trained to locate a hidden platform 
which was submerged 0.5 cm below the water surface. Training took 4 days, 4 trials per 
day, and 60 seconds per trial. On the 5th day, the platform was removed and a single 
probe trial lasting 30 seconds was performed;  time spent swimming in the target 
quadrant where the platform was located was recorded. 
2.11 Statistical Methods 
All histological data were analyzed using Prism 5.0 (GraphPad Sofware, Inc). 
Shapiro Wilk tests were used to assess normal distribution of data. Mann Whitney U-
tests were used to compare levels of Aβ and phospho-tau in hippocampal lysates of 
injured and sham 3xTg-AD mice, since the distribution of data was not normal. For 
pairwise comparisons of quantitative immunochemical data (e.g. injured vs. sham, drug 
vs. vehicle), one-sided Student’s t-tests were used in these cases because unidirectional 
hypotheses were pre-specified.  For changes of either Aβ or tau pathology as function 
of time or injury severities, one-way ANOVAs with Newman-Keuls post tests were 
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used because there were no prespecified hypotheses about the direction of change. For 
pairwise comparisons of Aβ immunohistochemical data between injured 3xTg-AD and 
APP/PS1 mice, and of tau immunohistochemical data between 3xTg-AD and TauP301L 
mice, student’s t-tests were employed. Kruskal-Wallis with Dunn’s post hoc tests were 
used for pairwise comparison of hippocampal and fimbria volumes between groups. 
Values are expressed as means ± SEM. Statistical significance was set at p < 0.05. 
For pairwise comparisons of levels of tau kinases via western blot and 
immunohistochemistry and phosphatase activity between TBI and sham mice, two-
tailed student’s t-tests were used; p values of < 0.05 were considered significant. For 
comparisons of staining areas covered by activated kinases in the fimbria/fornix, a one-
way ANOVA with Neuman-Keuls post-test was used. Values are expressed as means ± 
SEM. 
For pairwise comparisons of quantitative histological data of D-JNKi1 
experiments (e.g. D-JNKi vs. D-TAT), one-sided Student’s t-test were used because 
unidirectional hypotheses were prespecified. There was a trend toward reduced tau 
pathology when we first analyzed results from 5 D-JNKi1 and 4 D-TAT treated mice. 
Therefore, additional 4 mice were added to each group, and data were re-analyzed. As 
such, statistical significance for these analyses was set to p < 0.025 due to the optional 
stopping design of the experiment. Values are expressed as means ± SEM. 
Behavioral data were analyzed using Statistica 6.0 (Stat-Soft). Repeated measures 
ANOVA was used to compare visible and hidden platform performance on the Morris 
water maze task. Statistical significance was set to be < 0.05. Values are means ± SEM, 
unless otherwise noted. 
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Chapter 3 
Characterization of  the Acute Aβ and 
Tau Pathologies post TBI in Young 
3xTg-AD Mice 
3.1 Introduction 
Traumatic brain injury (TBI) is a strong environmental risk factor for 
subsequent development of a number of neurodegenerative diseases, including 
Alzheimer’s disease (AD). Pathological hallmarks of AD are extracellular deposition of 
amyloid-β (Aβ) plaques and intracellular accumulation of neurofibrillary tangle (NFT) 
containing hyperphosphorylated tau protein. Accumulations of Aβ and tau proteins are 
also thought to be among secondary insults that cause undesirable cognitive outcomes 
following TBI.  Specifically, intra-axonal Aβ accumulation has been observed within 
hours to days following TBI in brains of young individuals who do not have preexisting 
neurodegeneration (Clinton et al., 1991; Roberts et al., 1991; Uryu et al., 2002; Smith et 
al., 2003b; Smith et al., 2003d; Chen et al., 2009). In addition, co-accumulations of APP, 
BACE1 (β-secretase), PS1, caspase-3, and Aβ have been observed in injured axons of 
human TBI patients (Smith et al., 2003c; Chen et al., 2009). These data provide basis for 
TBI, particularly traumatic axonal injury as the underlying mechanism for post-
traumatic increase in Aβ production and aggregation. Moreover, accumulation of total 
and phospho-tau in injured axons have sometimes been observed in individuals 
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subjected to single severe TBI (Ikonomovic et al., 2004; Uryu et al., 2007). Meanwhile, 
exacerbation of NFT-containing tau has been extensively observed in individuals 
subjected to repetitive, concussive TBI (Corsellis and Brierley, 1959; Corsellis, 1989; 
Roberts et al., 1990; Geddes et al., 1999); this pathology positively correlates with 
cognitive impairments and brain atrophy. Thus, TBI can also play a causal role in 
acceleration of tau pathology. Although these post-traumatic Aβ and tau accumulations 
have been recapitulated in experimental TBI in pigs (Smith et al., 1999b), it is difficult to 
perform mechanistic studies using this model organism. Subsequently, attempts have 
been made to subject transgenic mice producing either human Aβ or tau to 
experimental TBI. For instance, acute increase in total Aβ in tissue homogenates has 
been observed in an APP transgenic line which has undergone controlled cortical 
impact TBI (Smith et al., 1998). Repetitive TBI has been shown to accelerate plaque 
pathology in another APP transgenic line at 16 weeks following injury (Uryu et al., 
2002), while the same injury paradigm in a tau transgenic line only resulted in tau 
exacerbation in 1 of 12 animals (Yoshiyama et al., 2005). None of these models reliably 
reproduced both Aβ and tau features observed in humans, nor did they allow 
assessment of the interaction between human Aβ and tau (Johnson et al., 2010). 
It is therefore crucial to develop a new experimental TBI mouse model to better 
understand pathophysiological mechanisms underlying the association of TBI to AD 
pathologies. Toward this end, we performed CCI TBI on young 3xTg-AD mice, a 
transgenic line that expresses both human forms of Aβ and tau. We characterized the 
acute spatial and temporal changes of Aβ and tau following injury in this section. 
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3.2 Characterization of the Acute Aβ 
Pathology following TBI in Young 3xTg-
AD Mice 
3.2.1 Axonal Aβ Pathology at 24 h post Injury in 3xTg-AD 
Mice 
Acute intra-axonal Aβ accumulation is a prevalent feature of human traumatic 
axonal injury (Smith et al., 2003c; Uryu et al., 2007; Chen et al., 2009). Because of the 
age-related intra-axonal Aβ accumulation in 3xTg AD mice, we hypothesized that these 
animals would be useful in the assessment of TBI-related axonal Aβ pathology. More 
specifically, we hypothesized that experimental TBI would accelerate intra-axonal Aβ 
pathology in young 3xTg-AD mice. To test this hypothesis, we subjected these mice to 
controlled cortical impact TBI, as detailed (Brody et al., 2007). Mice were subjected to 
moderately severe injury: 2.0 mm below the dura. This resulted in significant 
hippocampal damage and behavioral deficits but low mortality, as described (Brody et 
al., 2007). Mice were sacrificed at 24 h following TBI; their brains were then processed 
and examined immunohistochemically for Aβ pathology. Negative controls included 
age-matched, sham 3xTg-AD mice (which underwent the same anesthesia and surgical 
procedures but were not injured), injured wild-type B6/SJL mice (2.0 mm), and 
omission of primary antibodies. The positive controls for Aβ staining were brain slices 
from 20 month old PDAPP mice (Games et al., 1995).  
We found Aβ accumulations in pericontusional white matter of injured, young 
3xTg-AD mice. The ipsilateral fimbria/fornix appeared to have the most prominent Aβ 
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accumulation (Figure 3.1A). These Aβ accumulations had spheroidal and ‘beads-on-a-
string’ morphologies, consistent with the morphology of injured axons (Figure 3.1D, 
G, J, M, P).The specificity of this Aβ staining was confirmed with five Aβ specific 
antibodies: pan-Aβ against Aβ15-30 (Figure 3.1D), monoclonal 3D6 against Aβ1-5 (Figure 
3.1G), monoclonal HJ3.4 against Aβ1-13 (Figure 3.1J) polyclonal C-terminal antibody 
against Aβ35-40 (Figure 3.1M), and polyclonal C-terminal antibody against Aβ35-42 
(Figure 3.1P). No Aβ staining was observed when primary antibodies were omitted 
(Figure 3.1S). No such axonal Aβ pathology was observed in sham (non-injured), age-
matched 3xTg-AD mice (Figure 3.1B, E, H, K, N, Q), nor in injured wildtype mice 
(Figure 3.1C, F, I, L, O, R).  Aβ was also observed in pericontusional hippocampal 
commissure, corpus callosum, and external capsule of injured 3xTg-AD mice, though to 
a lesser extent than the fimbria/fornix (Figure 3.2). 
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Figure 3.1 Controlled cortical impact TBI caused Aβ accumulation in ipsilateral 
fimbria/fornix of young 3xTg-AD mice. 
A-C. Aβ immunohistochemistry from an injured 3xTg-AD mouse, a sham 3xTg-AD mouse, 
and an injured wildtype mouse, respectively. Scale bar: 2 mm. D-R. Higher magnification of the 
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ipsilateral fimbria/fornix (boxes in A-C). Scale bar: 50 µm. Presence of intra-axonal Aβ in the 
ipsilateral fimbria/fornix of a moderately injured 3xTg-AD mouse was confirmed using panAβ, 
a polyclonal antibody against amino acids 15-30 of Aβ (D-F), 3D6, a monoclonal N-terminus 
antibody against amino acids 1-5 of Aβ (G-I), HJ3.4, a monoclonal N-terminus antibody against 
amino acids 1-13 of Aβ (J-L), Aβ40, a polyclonal C-terminus antibody against amino acids 35-40 
of Aβ (M-O), and Aβ42, a polyclonal C-terminus antibody against amino acids 35-42 of Aβ (P-
R). No Aβ immunoreactivity was observed in sham 3xTg-AD mice and injured wildtype mice. 
S. No Aβ immunoreactivity was observed in injured 3xTg-AD mice when primary antibody was 
omitted. T. Schematic of anti-Aβ antibodies used. 
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Figure 3.2 Controlled cortical impact TBI caused intra-axonal Aβ accumulation in 
pericontusional white matter tracts of young 3xTg-AD mice. 
A-B. Aβ staining with panAβ antibody (against Aβ15-30) in an uninjured (sham) and an injured 
(TBI) 3xTg-AD mouse. Scale bar: 2 mm. C-J. Higher magnification of intra-axonal Aβ 
accumulation in the ipsilateral fimbria (C-D, black box in A-B), ipsilateral hippocampal 
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commissure (E-F, blue box in A-B), ipsilateral corpus callosum (G-H, red box in A-B) and 
ipsilateral external capsule (I-J, purple box in A-B). Scale bar in C: 50 µm. Most prominent Aβ 
staining was observed in the ipsilateral fimbria/fornix of injured mice. Aβ staining has beads-
on-a-string and varicose morphologies, consistent with morphologies of injured axons.  
 
To further confirm the immunohistochemical findings, human specific Aβ1-x, 
Aβ1-40, and Aβ1-42 ELISAs were employed to assess Aβ levels in hippocampal lysates of 
these moderately injured and sham 3xTg-AD mice. Both ipsilateral and contralateral 
hippocampi were assessed. These tissues were subjected to serial homogenization in 
TBS, Carbonate, and 5M Guanidine. This serial homogenization method produces 
extracts enriched in soluble Aβ from the extracellular compartment, soluble Aβ from 
intracellular compartments and residual insoluble Aβ, respectively. While there were 
similar levels of total Aβ (Aβ1-x) in TBS and carbonate lysates in both ipsilateral and 
contralateral hippocampi (Figure 3.3A-B), a significant increase in insoluble total Aβ 
was detected in 5M Guanidine ipsilateral hippocampal lysates of injured as compared to 
sham 3xTg-AD (Mann Whitney U-test, p = 0.0047, Figure 3.3C). There was a non-
significant trend toward increased Guanidine total Aβ levels in the contralateral 
hippocampi of injured mice compared to sham (Figure 3.3C). Furthermore, we found a 
significant increase in Aβ1-40 and a trend toward increased Aβ1-42 in the ipsilateral 
hippocampal lysates of injured 3xTg-AD mice (Figure 3.3D-E).  Overall, these data are 
concordant with the immunohistochemical evidence of intracellular Aβ accumulation 
following TBI in these mice.  
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Figure 3.3 Controlled cortical impact TBI resulted in increased levels of relatively 
insoluble Aβ in 3xTg-AD mice. 
Ipsilateral and contralateral hippocampal tissues of injured (2.0 mm) and sham 3xTg-AD mice 
were sequentially homogenized in TBS, carbonate, and guanidine buffers. TBS and carbonate 
lysates contain mostly soluble Aβ species; guanidine lysates are composed of relatively insoluble 
Aβ species. A. Total Aβ levels in TBS lysates of ipsilateral and contralateral hippocampi of sham 
and injured mice. B. Total Aβ levels in Carbonate lysates of ipsilateral and contralateral 
hippocampi of sham and injured mice. C. Total Aβ levels in guanidine lysates ipsilateral and 
contralateral hippocampi of sham and injured mice. Significantly more total Aβ levels were 
observed ipsilateral hippocampi, but not contralateral hippocampi of injured than sham mice 
(*** p = 0.0047, Mann Whitney U-test). D. Aβ1-40. E. Aβ1-42 levels in guanidine lysates of 
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ipsilateral hippocampi of sham and injured mice. Significantly more Aβ1-40 and a trend toward 
increase in Aβ1-42 were observed in ipsilateral guanidine hippocampal lysates of injured 
compared to sham mice (* p = 0.013, ns: not significant, Mann Whitney U-test). N = 7-8 mice 
per group. Bars represent mean ± SEM.  
 
To summarize, intra-axonal Aβ accumulation appeared consistently in 3xTg-AD 
mice following experimental TBI. This intra-axonal Aβ appeared to be in a relatively 
insoluble form. 
3.2.2 Axonal Aβ Pathology from 1 h to 24 h post TBI in 
3xTg-AD Mice 
Since Aβ accumulation has been detected as early as 2 h post TBI in humans 
(Ikonomovic et al., 2004), we tested the hypothesis that TBI causes very early axonal Aβ 
accumulation in 3xTg-AD mice by sacrificing independent groups of mice at 1, 6, 9, 12, 
and 24 h post injury. We analyzed Aβ axonal pathology with HJ3.4 antibody against 
Aβ1-13 in these studies. To demonstrate that HJ3.4 recognizes only Aβ, but not APP, we 
performed an immunoprecipitation, followed by a Western blot analysis. Identical 
aliquots (100 µg) from brain lysates of a 9 month-old 3xTg-AD mouse was 
immunoprecipitated with monoclonal HJ3.4, 82E1, 6E10 antibodies, or no primary 
antibody control. Monoclonal 82E1 has been previously shown to be specific for Aβ 
(Osawa et al., 2008; Winton et al., 2011), while monoclonal 6E10 antibody can 
recognize both Aβ and APP (Winton et al., 2011). The resultant immunodepleted 
supernatants were subjected to Western blotting with 6E10 antibody. Our data 
demonstrated that HJ3.4 antibody, similar to 82E1 antibody, does not recognize APP 
(Figure 3.4 A).  We found Aβ in injured axons at all time points following injury 
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(Figure 3.4 C-G). Morphologies of Aβ-positive axonal varicosities evolved from small 
swellings observed at 1 and 6 hours after injury (Figure 3.4 C-D) to larger spheroids, 
bulbs, and beaded varicose fibers at the later times (9, 12, and 24 h post TBI, Figure 
3.4 E-G). Stereological quantification revealed moderate numbers of injured axons with 
Aβ accumulation in some but not all mice at the earliest time points examined (1 h and 
6 h after injury, Figure 3.4 H). However, substantially greater numbers of Aβ-
immunoreactive axonal varicosities were present at later time points, and all mice 
sacrificed between 9 and 24 hours had this pathology (9, 12, and 24 h, Figure 3.4 H). 
The increase in Aβ-positive axonal varicosities between 6 and 9 hours after TBI was 
statistically significant, as was the increase between 12 and 24 hours (Figure 3.4 H, p < 
0.05).  
 
Figure 3.4 Intra-axonal Aβ accumulation monotonically increased from 1 to 24 hours 
post injury in 3xTg-AD mice. 
A. Immunoprecipitation (I.P) and Western blot (WB) showed that HJ3.4 antibody, similar to 
82E1 antibody, did not recognize APP, while, 6E10 antibody recognized APP; work done by TJ 
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Esparza. B..Aβ staining with biotinylated HJ3.4 antibody (against Aβ1-13) in the ipsilateral 
fimbria/fornix of a sham 3xTg-AD mouse. Sections were counterstained with cresyl violet. 
Scale bar: 50 µm.C-G. Aβ staining in the ipsilateral fimbria/fornix of an injured 3xTg-AD 
mouse at 1 h (C), 6 h (D), 9 h (E), 12 h (F) and 24 h (G) after TBI. H. Stereological 
quantification of total numbers of Aβ-positive axonal varicosities as a function of time after 
injury in 3xTg-AD mice. N = 4-8 mice per group per time point. Bars represent mean ± SEM. 
One-way ANOVA with Newman-Keuls post tests, # p < 0.05, ## p < 0.01: significant 
increase from injured mice from previous time point. ** p < 0.01, *** p < 0.0001: significant 
increase from sham mice at same time point.  
 
In summary, controlled cortical impact TBI consistently accelerated Aβ axonal 
accumulation in young 3xTg-AD mice. Aβ accumulation appeared as early as 1 h post 
TBI, and continued to rise through 24 h. 
3.2.3 Aβ Pathology as a Function of Injury Severity 
Previous studies have found that more severe TBI results in more APP 
accumulation in damaged axons (Blumbergs et al., 1994; Bramlett et al., 1997). Since Aβ 
is derived from proteolytic cleavage of APP and accumulates in axons of 3xTg-AD mice 
following TBI, we hypothesized there would be a correlation between axonal injury 
severity and extent of Aβ accumulation in these mice. To test this hypothesis, we 
performed additional mild (1.0 mm impact below dura) and mild-moderate (1.5 mm 
impact below dura) injuries on 3xTg-AD mice. We compared Aβ and APP-labeled 
axonal pathologies among the mild, mild-moderate, and moderate (2.0 mm) TBI groups 
using immunohistochemistry and stereological quantification. 
We found that both APP and Aβ accumulations in pericontusional white matter 
were dependent on injury severity in young 3xTg-AD mice. Specifically, few injured 
axons stained for APP were found in the ipsilateral fimbria/fornix of mildly injured 
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3xTg-AD mice (1.0 mm, Figure 3.5 B, F). Many more APP-stained axonal varicosities 
were observed in the same region in the other injured groups (1.5 mm and 2.0 mm, 
Figure 3.5 C, D, G,  H), but none in the sham injured ones (Figure 3.5 A, E). 
Furthermore, we found a parallel relationship between the extent of the axonal injury 
and the amount of intra-axonal Aβ in the fimbria/fornix (Figure 3.5 I-L). Markedly 
fewer APP- and Aβ- stained varicosities were observed in other injured white matter 
regions such as the ipsilateral pericontusional hippocampal commissure, ipsilateral 
external capsule, and ipsilateral corpus callosum. In these other regions, the extent of 
both APP and Aβ staining was similarly dependent on injury severity (Figure 3.6).   
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Figure 3.5 Aβ accumulation varied with injury severity and colocalized with markers of 
axonal injury in 3xTg-AD mice. 
A-D. APP immunohistochemistry (IHC) of sham, mildly (1.0 mm), mild-moderately (1.5 mm), 
and moderately (2.0 mm) injured, young 3xTg-AD mice. Scale bar: 2 mm. E-H. Higher 
magnification of axonal injury detected by APP IHC in the ipsilateral fimbria (boxes in A-D). 
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Scale bar: 50 µm. I-J. Intra-axonal Aβ IHC in the ipsilateral fimbria using pan-Aβ antibody 
against Aβ15-30. M. Stereological quantification of numbers of APP-stained varicosities per cubic 
mm of the ipsilateral fimbria as a function of injury severity. N. Stereological quantification of 
numbers of Aβ-stained varicosities per cubic mm of the ipsilateral fimbria as a function of injury 
severity. Bars represent mean ± SEM. One-way ANOVA with Newman-Keuls post-hoc test, ** 
p < 0.01, *** p < 0.005, ns: not significant. O. Pearson’s correlation of numbers of Aβ- and 
APP-stained varicosities in injured fimbria, r2 = 0.53, p = 0.0015. N = 5-6 mice per injury 
severity. P. Colocalization of Aβ with APP in injured fimbria of a 3xTg-AD mouse. Scale bar: 
50 µm. Q. Colocalization of Aβ with neurofilament light chain 68kD (NF-L68), another marker 
of axonal injury, in injured fimbria of a 3xTg-AD mouse. Aβ was detected with monoclonal 
3D6 antibody conjugated to Alexa Fluor® 594 (red). This antibody requires a free amino 
terminus of Aβ for binding and does not cross react with APP. APP and NF-L68 were 
visualized with secondary antibody conjugated to Alexa Fluor® 488 (green).  
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Figure 3.6 APP and Aβ accumulations in other white matter regions of injured 3xTg-AD 
mice varied with injury severity. 
Aβ staining was performed with polyclonal panAβ antibody. A-I. APP staining of injured axons 
in hippocampal commissure (A-C), corpus callosum (D-F), and external capsule (G-I) of mice 
subjected to mild, mild-moderate, and moderate TBI, respectively. Scale bar: 50 µm. J-R. Aβ 
staining of injured axons in the hippocampal commissure (J-L),  corpus callosum (M-N), and 
external capsule (P-R) of 3xTg-AD mice subjected to mild, mild-moderate, and moderate TBI. 
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To quantitatively characterize the observed relationship between injury severities 
and the extent of APP and Aβ accumulations in injured axons of the fimbria/fornix, we 
employed the optical fractionator stereological method. We found significantly more 
APP-stained varicosities in the mild-moderate and moderate TBI groups compared to 
the mild TBI group (Figure 3.5 M, One-way ANOVA, p < 0.0001).There was a trend 
toward increasing number of APP-stained varicosities in the moderate TBI group (2.0 
mm) as compared to the mild-moderate TBI group (1.5 mm), but this was not 
statistically significant (Figure 3.5 M). A similar relationship between injury severities 
and numbers of Aβ-stained varicosities was observed: the more severe the injury, the 
more intra-axonal Aβ accumulation (Figure 3.5 N, One-way ANOVA, p = 0.0005). 
There was a statistically significant positive correlation between the numbers of APP- 
and Aβ-stained varicosities (Figure 3.5 O, Pearson r2 = 0.53, p = 0.0015).  
To determine definitively whether these accumulations of Aβ were found within 
injured axons, we performed double immunofluorescence labeling of Aβ and APP and 
separate double immunofluorescence with the 68kD neurofilament light chain subunit, 
NF-L68. APP and NF-L68 are well-established axonal markers and accumulations of 
both proteins are robust signatures of axonal injury (Gennarelli et al., 1982; Yaghmai 
and Povlishock, 1992; Gentleman et al., 1993; Grady et al., 1993; Christman et al., 1994; 
Sherriff et al., 1994a; Graham et al., 1995; Povlishock and Christman, 1995; Chen et al., 
1999; Smith et al., 1999b; Stone et al., 2000, 2001; Marmarou et al., 2005). They have 
been shown to extensively colocalize with Aβ in injured axons from human TBI 
patients (Smith et al., 2003c; Uryu et al., 2007; Chen et al., 2009). We found that 
essentially all Aβ-immunoreactive axonal varicosities in injured 3xTg-AD mice were also 
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positive for APP and NF-L68 on confocal microscopy (Figure 3.5 P-Q). Aβ labeling 
was performed using the monoclonal anti-Aβ antibody 3D6 directly conjugated to 
Alexa Fluor® 594; 3D6 does not cross react with APP as it requires a free amino-
terminus to bind (Johnson-Wood et al., 1997). No such colocalization was observed in 
sham 3xTg-AD mice (data not shown), nor when one of the primary antibodies was 
omitted (data not shown).  
Thus, controlled cortical impact TBI in 3xTg-AD mice reproduced one of the 
hallmark features of human post-TBI neurodegenerative pathology: intra-axonal Aβ 
accumulation at sites of traumatic axonal injury. Moreover, Aβ colocalized with markers 
of axonal injury, and correlated with severity of axonal injury. 
3.3 Characterization of the Acute Tau 
Pathology post TBI in 3xTg-AD Mice  
3.3.1 Tau Pathology at 24 h post TBI in 3xTg-AD Mice 
We next investigated the effects of TBI on tau accumulation and 
phosphorylation in the same injured and sham 3xTg-AD mice. We first performed 
immunohistochemistry using polyclonal tau antibody (pAb Tau) and monoclonal HT7 
which recognize both normal and hyperphosphorylated human tau. Negative controls 
included injured wild-type mice and omission of primary antibodies. Brain slices from 
12 month old 3xTg-AD mice served as a positive control.  
In the pericontusional fimbria/fornix, abnormal punctate tau immunoreactivity 
was observed following moderate TBI in 3xTg-AD mice (Figure 3.7 A, D). There was 
minimal tau staining in the same region of sham injured mice (Figure 3.7 B, E), and 
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none in moderately injured wildtype mice (Figure 3.7 C, F). Interestingly, there were 
two additional regions in which there were marked increase in tau immunoreactivity in 
injured as compared to sham 3xTg-AD mice. These were the ipsilateral amygdala and 
contralateral CA1 regions (Figure 3.7 A-B, G-H, J-K). Tau immunoreactivity in the 
amygdala had a perinuclear cytoplasmic distribution, while that in the contralateral CA1 
took the appearance of elongated neurites. These regions are distant from the site of 
injury but are anatomically connected to the ipsilateral hippocampus via the ipsilateral 
fimbria/fornix tract (Witter and Amaral, 2004). Similar patterns of tau staining were 
observed in injured and sham 3xTg-AD mice when monoclonal HT7 against total tau 
was used (Figure 3.7 M-N, P-Q, S-T). No total tau immunoreactivity was observed in 
injured wildtype mice (Figure 3.7 C, F, I, L, O, R, U). Total tau immunoreactivity in 
the ipsilateral hippocampus was not significantly affected by TBI in these mice (data not 
shown). 
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Figure 3.7 TBI accelerated tau pathology in young 3xTg-AD mice. 
Total tau (independent of phosphorylation state) was detected with polyclonal total tau antibody 
(pAb Tau) and HT7 monoclonal antibody. A-C. pAb tau staining in injured 3xTg-AD mice, 
sham 3xTg-AD mice and injured wildtype mice, respectively. D-F. Higher magnification of the 
ipsilateral fimbria (black boxes in A-C). G-I. Higher magnification of the ipsilateral amygdala 
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(green boxes in A-C). J-L. Higher magnification of the contralateral CA1 (purple boxes in A-C). 
M-U. Total tau staining using HT7 antibody. More tau-positive puncta were observed in 
ipsilateral fimbria of injured 3xTg-AD mice compared to sham 3xTg-AD mice. More tau-
positive somata were present in ipsilateral amygdala of injured compared to sham 3xTg-AD 
mice. More tau-positive processes were also observed in the contralateral CA1 of injured 
compared to sham 3xTg-AD mice. No tau immunoreactivity was observed in injured wildtype 
mice. 
 
To test whether TBI increased the extent of tau phosphorylation in 3xTg-AD 
mice, we performed additional immunohistochemical studies using polyclonal 
antibodies against phosphorylated tau in sham and moderately injured mice. Injured 
mice exhibited more phospho-tau staining than sham mice for all the phospho-tau 
antibodies used. Specifically, phospho-S199 tau was observed in ipsilateral hippocampal 
CA1 and fimbria of moderately injured mice (Figure 3.8 A, C). Immunoreactivity for 
phospho-T205 was prominent in ipsilateral fimbria only (Figure 3.8 E). Tau also 
appeared to be heavily phosphorylated at T231, S396, and S422 in fimbria of 3xTg-AD 
mice following TBI (Figure 3.8 G, I, K). No phospho-tau immunoreactivity was 
observed in sham 3xTg-AD mice at 6 months of age (Figure 3.8 B, D, F, H, J, L). 
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Figure 3.8 Controlled cortical impact TBI increased levels of phospho-tau 
immunoreactivity in ipsilateral hippocampi and fimbria of young 3xTg-AD mice. 
A-D. Tau staining of moderate TBI (2.0 mm) and sham 3xTg-AD mice using polyclonal 
antibody against phosphorylated tau at S199. Scale bar: 50 µm. A-B. Ipsilateral hippocampal 
CA1. C-D. Ipsilateral fimbria. E-L. Phospho-tau staining in fimbria of TBI and sham 3xTg-AD 
mice using polyclonal antibodies against tau phosphorylated at T205 (E-F), T231 (G-H), S396 
(I-J), and S422 (K-L). M. Representative AT8 western blot of ipsilateral hippocampi from 2.0 
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mm TBI and sham 3xTg-AD mice. AT8 blots were stripped and reprobed with Tau46 antibody 
for total tau. A significant increase in ratio of AT8 to Tau46 band densities was observed 
following TBI. (*** p = 0.0006, Mann-Whitney U Test)  N. Representative AT100 western blot 
of ipsilateral hippocampi from 2.0 mm TBI and sham 3xTg-AD mice. A significant increase in 
ratio of AT100 to Tau46 band densities was observed following TBI. (* p = 0.03, Student’s t-
test). O. Representative AT180 western blot of ipsilateral hippocampi from 2.0 mm TBI and 
sham 3xTg-AD mice. A significant increase in ratio of AT180 to Tau46 band densities was 
observed following TBI. (* p = 0.03, Student’s t-test.)  N = 7-8 mice per group. Bars represent 
mean ± SEM.  
 
To further confirm these findings, separate groups of sham and moderately 
injured mice were sacrificed at 24 h by rapid decapitation. Bilateral hippocampi were 
quickly removed and frozen. Tissue were homogenized in RIPA buffer and subjected to 
western blotting using the monoclonal AT8 antibody against phosphorylated tau at 
S199 or S202 and T205, the AT100 antibody against phosphorylated tau at T212 and 
S214, and the AT180 antibody against phosphorylated tau at T231 (Mercken et al., 
1992). Blots were stripped and reprobed with the Tau46 antibody to quantify total tau.  
We found marked increases in the densities of AT8, AT100, and AT180 
immunoreactive bands in injured compared to sham 3xTg-AD mice, indicating an 
increase in levels of tau phosphorylation (Figure 3.8 M-O).  Total tau levels in these 
samples appeared slightly lower in the injured mice (Figure 3.8 M). Overall, there were 
approximately two-fold increases in the ratio of AT8, AT100, and AT180 
immunoreactive phospho-tau band densities to total tau band densities following TBI in 
3xTg-AD mice (Figure 3.8 M-O, Mann Whitney U-test, p < 0.05). No such 
immunoreactivity for tau was observed when primary antibody was omitted (Figure 3.9 
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A). No increases in tau phosphorylation were detected in contralateral hippocampal 
lysates (Figure 3.9 B-C). 
 
 
Figure 3.9 Negative control and western blotting of contralateral hippocampal lysates. 
A. Negative control: Western blot of hippocampal lysates from moderate TBI (T) and sham (S) 
3xTg-AD mice when primary antibody was omitted and secondary anti-mouse antibody-
conjugated to HRP was applied. No signal was observed. B. Ratio of AT8 to Tau46 from 
contralateral hippocampal lysates of injured and sham mice. C. Ratio of AT100 to Tau46 from 
contralateral hippocampal lysates of injured and sham mice. Bars represent mean ± SEM. N=7-
8 mice per group. Student’s t-tests, not significant. 
 
In summary, experimental TBI caused increased tau immunoreactivity in young 
3xTg-AD mice. Notably, the spatial distribution of TBI-related changes in tau 
immunoreactivity was distinct from those of post-injury Aβ. Levels of tau 
phosphorylation were significantly increased following TBI, based on both biochemical 
and immunohistochemical analyses. 
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3.3.2 Tau Pathology from 1 h to 24 h post TBI in 3xTg-AD 
Mice 
We investigated the temporal patterns of tau accumulation in ipsilateral fimbria, 
ipsilateral amygdala, and contralateral CA1 using the same mice used to assess the time 
course of Aβ described above. We quantitatively characterized the time course of tau 
immunoreactive changes using stereological methods (Figure 3.10 I, P, W). In the 
ipsilateral fimbria, there were significantly elevated numbers of tau-positive puncta at 1 
h and 24 h, but not at 6 h – 12 h following injury (Figure 3.10 C-H). In sham mice, 
there were 3,420 ± 919, whereas at 1 h post injury, there were 69,641 ± 8,496 (p < 0.05) 
and at 24 h there were 138,887 ± 35,543 (p < 0.0001) tau-stained puncta per cubic 
millimeter of fimbria (Figure 3.10 I). 
Tau immunoreactivity in cell bodies of the ipsilateral amygdala exhibited a 
similar biphasic time course: the numbers of immunoreactive cell bodies were increased 
at 1 h following injury (Figure 3.10 K), came back to sham levels from 6 h to12 h 
(Figure 3.10 L-N), and rose again at 24 h (Figure 3.10 O). Since there was substantial 
tau immunoreactivity in sham 3xTg-AD mice in this region (Figure 3.10 J), 
stereological quantification of numbers of tau-positive somata was expressed as percent 
of sham. While numbers of tau-positive cell bodies from 6 h to 12 h after injury were 
similar to sham, significantly more were apparent at 1 h and 24 h in ipsilateral amygdala 
after injury (Figure 3.10 P, p < 0.05).  
Interestingly, the temporal profile of tau-positive processes in the contralateral 
hippocampal CA1 region followed a different pattern, with a delayed monophasic rise. 
Specifically, the extent of tau immunoreactivity in contralateral CA1 in uninjured 3xTg-
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AD mice and injured mice sacrificed from 1 h to 9 h following injury appeared similar 
(Figure 3.10 Q-T). From 12 h after TBI, however, tau immunoreactivity in this region 
increased (Figure 3.10 U-V). Stereological quantification of total length of tau-positive 
process using the spherical probes (also known as ‘spaceballs’) method indicated a 
significant increase from sham starting at 12 h following injury (Figure 3.10 W, p < 
0.05); this measure stayed elevated at 24 h (Figure 3.10 V, W). 
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Figure 3.10 Time course of TBI-induced tau pathology was distinct in several brain 
structures of 3xTg-AD mice. 
Tau staining was with polyclonal total tau antibody. A-B. Tau staining in a sham (A) and an 
injured (B) 3xTg-AD mouse. Three regions with accelerated tau pathology compared to sham at 
24 h post TBI were the ipsilateral fimbria/fornix (black box), ipsilateral amygdala (green box), 
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and contralateral CA1 (purple box). Scale bar: 2 mm. C-H. Higher magnification of punctate 
tau staining in the ipsilateral fimbria (black box in A-B) of a sham (C) and injured 3xTg-AD 
mice at 1 h (D), 6 h (E), 9 h (F),12 h (G), and 24 h (H) following TBI. Scale bar in C: 50 µm. I. 
Stereological quantification of numbers of tau-positive puncta per cubic millimeter in ipsilateral 
fimbria as a function of time post injury. J-O. Perinuclear, cytoplasmic tau staining in somata of 
the ipsilateral amygdala (green box in A-B). P. Stereological quantification of numbers of tau-
positive somata per cubic millimeter in the ipsilateral amygdala as a function of time post injury. 
Q-V. Tau staining in processes of the contralateral CA1 (purple box in A-B). W. Stereologcial 
quantification of tau-positive processes of CA1 pyramidal neurons per cubic millimeter as a 
function of time post injury. N = 4-8 mice per group per time point. Bars are mean ± SEM in 
fimbria, and percent of sham ± SEM for amygdala and CA1 region. One-way ANOVA with 
Newman-Keuls post tests, * p < 0.05, ** p < 0.01, *** p < 0.001: significant increase from 
sham mice at same time point. # p < 0.05: significant increase from injured mice at previous 
time point.  
 
Thus, experimental TBI increased tau immunoreactivity in a multifocal fashion 
in the brains of 3xTg-AD mice. A two-phase increase in tau immunoreactivity was 
observed at 1 hour and 24 hours after TBI in the ipsilateral fimbria and ipsilateral 
amygdala, while only a single phase was observed at 12-24 hours in the contralateral 
hippocampal CA1 region. Notably, the spatiotemporal distribution of TBI-related 
changes in tau immunoreactivity was distinct from those of post-injury Aβ 
accumulation.  
3.3.3 Effects of Injury Severity on Tau Pathology at 24 h 
post TBI in 3xTg-AD Mice 
Next, we examined the effects of varying injury severity on total tau pathology 
in 3xTg-AD mice (Figure 3.11 B-D). Abnormal tau-positive puncta in the ipsilateral 
fimbria appeared to increase in an injury severity dependent manner (Figure 3.11 F-H). 
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There was minimal tau staining in the same region of sham injured mice (Figure 3.11 A, 
E). Only in the moderate TBI group were there more tau-positive somata in the 
ipsilateral amygdala and tau-positive neurites in the contralateral CA1 (Figure 3.11 I-P). 
No tau immunoreactivity was observed in injured 3xTg-AD mice when the primary 
antibody was omitted (data not shown).  
Quantitative analyses of tau immunoreactivity in these regions using stereology 
confirmed the qualitative histological findings. There were significantly more tau-
positive puncta in ipsilateral fimbria/fornix as the injury became more severe (Figure 
3.11 Q, One-way ANOVA, p < 0.0001). In the moderately injured group (2.0 mm), 
there was a significant increase in tau-positive somata in the ipsilateral amygdala 
compared to other TBI and sham groups (Figure 3.11 R, One-way ANOVA, p = 
0.008).  Likewise, tau-positive neurite length density in the contralateral CA1 of these 
moderately injured mice was significantly greater than the length density in the other 
groups (Figure 3.11 S, One-way ANOVA, p = 0.0079).  
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Figure 3.11 Tau pathology varied with injury severity in young 3xTg-AD mice. 
A-D. pAb Tau IHC of sham, mildly (1.0 mm), mild-moderately (1.5 mm), and moderately (2.0 
mm) injured, young 3xTg-AD mice. Scale bar: 2 mm. E-H. Higher magnification of tau staining 
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in the ipsilateral fimbria (black boxes in A-D). Scale bar: 50 µm. I-L. Higher magnification of 
tau staining in the ipsilateral amygdala (green boxes in A-D). M-P. Higher magnification of tau 
staining in the contralateral CA1 (purple boxes in A-D). Q. Stereological quantification of 
numbers of tau-stained punctate varicosities per cubic mm of the ipsilateral fimbria as a 
function of injury severity. R. Stereological quantification of numbers of tau-stained somata per 
cubic mm of the ipsilateral amygdala as a function of injury severity. S. Stereological 
quantification of tau-immunoreactive neuritic processes per cubic mm of the contralateral CA1 
as a function of injury severity. N = 5-6 mice per injury severity. Bars represent mean ± SEM. 
One-way ANOVA with Newman-Keuls post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.005. 
 
In summary, tau pathology in different brain regions of injured 3xTg-AD mice 
exhibited distinct responses to injury severity. 
3.4 Discussion of Acute Aβ and Tau 
Pathologies Observed in 3xTg-AD Mice 
post TBI 
In summary, controlled cortical impact TBI in 3xTg-AD mice recapitulated two 
key features observed post TBI in human. First, TBI caused rapid Aβ accumulation in 
injured axons of young 3xTg-AD mice. This intra-axonal Aβ was detectable at 1 hour 
post injury, and continued to rise monotonically through 24 hours. This is similar to the 
intra-axonal Aβ accumulation observed in human TBI patients (Smith et al., 2003c; 
Ikonomovic et al., 2004; Uryu et al., 2007; Chen et al., 2009). No such accumulation is 
expected at this age and none was seen in sham-injured mice. Second, TBI increased tau 
immunoreactivity in three distinct brain regions of moderately injured 3xTg-AD mice. 
The time course was different across regions. In particular, puntate tau staining the 
ipsilateral fimbria and perinuclear tau staining in the amygdala had a biphasic response 
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with peaks at 1 hour and 24 hours post TBI. Instead, the numbers of tau-positive 
processes in the contralateral CA1 started to increase at 12 h post injury. There was also 
immunohistochemical and biochemical evidence for increased tau accumulation and 
phosphorylation induced by TBI at several epitopes. 
Axonal injury appears necessary for post-traumatic Aβ accumulation in this 
model, as the extent of intra-axonal Aβ accumulation correlated well with injury severity 
and no Aβ was detected immunohistochemically in areas without axonal injury. Aβ was 
found colocalized with the axonal injury markers APP and NFL-68 in injured 3xTg-AD 
mice. Histological findings of Aβ accumulation following TBI were further confirmed 
biochemically; there was approximately twice the amount of insoluble total Aβ and Aβ40 
in ipsilateral hippocampal tissues of moderately injured as compared to uninjured mice.  
The significant increase in only Aβ40 levels following TBI in these mice may be related 
to the lack of extracellular Aβ plaques observed by immunohistochemistry. 
APP, the precursor protein of Aβ, has been found to accumulate in injured 
axons within 30 minutes following central nervous system injury (Dikranian et al., 
2008). Axonal APP accumulation has in turn been hypothesized to serve as substrate 
for intra-axonal Aβ generation (Smith et al., 2003c; Chen et al., 2004). Thus, our finding 
that intra-axonal Aβ was detected starting at 1 hour post TBI in 3xTg-AD mice is in line 
with the reported time for the earliest APP accumulation following brain trauma. 
Our mouse model recapitulates one aspect of post-traumatic Aβ pathology in 
human TBI:  intra-axonal Aβ accumulation. Neither our model nor other small animal 
experimental TBI models of which we are aware result in acute extracellular plaques. 
Interestingly, recent findings suggest that intracellular Aβ buildup is an early event in 
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Alzheimer’s disease pathogenesis, preceding plaque formation (Gouras et al., 2000; 
D'Andrea et al., 2001; Gyure et al., 2001; Mori et al., 2002a). Indeed, animal and cellular 
Alzheimer models have shown that the accumulation of intracellular Aβ species are 
neurotoxic and may be linked to synaptic dysfunction, cell loss, and memory 
impairment (Chui et al., 1999; Wirths et al., 2001; Zhang et al., 2002; Oddo et al., 2003a; 
Casas et al., 2004). Thus, our TBI mouse model of intra-axonal Aβ accumulation may 
emerge as an interesting model to study the relationship between TBI and Alzheimer’s 
disease. 
In addition to focal injuries, the controlled cortical impact TBI model employed 
in this study also affected distant regions such as the contralateral hippocampi and 
ipsilateral amygdala.  Evidence for this observation included a significant increase in 
total tau accumulation in the contralateral CA1 and ipsilateral amygdala of moderately 
injured mice. Interestingly, there was not a substantial increase in total tau accumulation 
in the ipsilateral hippocampus. Neuronal loss or injury may have caused release of tau 
into the extracellular space where it could not be detected by immunohistochemistry.  
The biphasic increase in tau immunoreactivity following TBI in ipsilateral 
fimbria and amygdala of 3xTg-AD mice is intriguing. Changes of tau immunoreactivity 
at 1 hour post TBI perhaps reflect an immediate response to mechanical injury.  
While axonal tau accumulation has been observed in a few cases of acute TBI in 
humans, the effects of injury severity on axonal tau accumulation, as described in this 
study, have not been documented. Likewise, the increased somatic tau accumulation in 
this model is rarely observed in human TBI (Ikonomovic et al., 2004). Thus, the 
relevance of these pathologies is not known.  
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In conclusion, this controlled cortical impact model using 3xTg-AD mice 
reproduced key features of human post-TBI AD-related pathology. It will likely allow 
many mechanistic hypotheses to be tested and may be useful for preclinical therapeutic 
development.   
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Chapter 4 
Investigation of  the Interaction between 
Aβ and Tau in the Setting of  TBI in 
3xTg-AD Mice 
4.1 Introduction 
Traumatic brain injury (TBI) can increase the risk for subsequent development 
of dementia of the Alzheimer’s type (Mortimer et al., 1991; Nemetz et al., 1999; 
Plassman et al., 2000; Fleminger et al., 2003). Pathological hallmarks of Alzheimer’s 
disease (AD) are extracellular plaques containing the amyloid-β (Aβ) peptides and 
neurofibrillary tangles (NFTs) containing hyperphosphorylated tau proteins.  
In mouse models of AD, Aβ pathology appears to be upstream of tau 
pathology. Three lines of experimental evidence support this relationship.  First, 
intracerebral injections of aggregated Aβ increased tau phosphorylation and therefore 
numbers of NFTs in TauP310L transgenic mice at both local and distant regions (Gotz et 
al., 2001). Second, double transgenic mice expressing both mutant APP and tau 
developed greater tau pathology than single tau transgenic mice (Lewis et al., 2001; 
Perez et al., 2005; Hurtado et al., 2010). Third, intracerebral injections of anti-Aβ 
antibodies in 3xTg-AD mice reduced both Aβ and tau pathology. Aβ pathology then 
recurred followed by later recurrence of tau pathology (Oddo et al., 2004). 
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On the other hand, the human pathological literature suggests that Aβ and tau 
pathologies may be independent in the setting of TBI, or at least that the relationship 
may be more complex. First, in single severe TBI, intra-axonal Aβ and diffuse 
extracellular plaques occurred in about 30% of subjects (Roberts et al., 1991; Roberts et 
al., 1994; Uryu et al., 2007). Intra-axonal accumulations of total and phospho-tau, but 
not true NFT pathology, have been documented in a smaller number of cases (Smith et 
al., 2003a; Ikonomovic et al., 2004). In repetitive concussive TBI resulting in dementia 
pugilistica or chronic traumatic encephalopathy, the opposite relationship was found; 
100% of cases reported to date have had widespread NFTs, but a smaller subset had Aβ 
pathology (Corsellis and Brierley, 1959; Corsellis, 1989; Roberts et al., 1990; Tokuda et 
al., 1991; Geddes et al., 1996; Geddes et al., 1999; Schmidt et al., 2001; McKee et al., 
2009). Even when both pathologies were present, there was no indication that they 
colocalized. 
To investigate the relationship between Aβ and tau pathologies in the setting of 
TBI, we used our experimental TBI model on 3xTg-AD mice. In this section, we 
showed that controlled cortical impact TBI independently results in intra-axonal Aβ and 
tau accumulation and increased tau phosphorylation in 3xTg-AD mice. This model may 
be a useful tool for many mechanistic and preclinical therapeutic investigations into the 
association between TBI and Alzheimer’s disease. 
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4.2 Effects of Acute (24 h) γ-secretase 
Inhibition on Post-traumatic Aβ and Tau 
Abnormalities in 3xTg-AD Mice 
4.2.1 Effects of Acute γ-secretase Inhibition on Post-
traumatic Aβ Accumulation 
The findings that both Aβ and tau pathologies were accelerated by controlled 
cortical impact allowed us the opportunity to investigate the interaction between Aβ and 
tau in the setting of TBI.   
To investigate the interaction between Aβ and tau pathologies, we blocked Aβ 
production using a γ-secretase inhibitor. γ-secretase is one of the canonical enzymes 
required for proteolytic processing of APP to form Aβ (Selkoe, 2001). If tau is 
downstream of Aβ in the setting of TBI, we expected to see amelioration of tau 
abnormalities after blocking Aβ production. However, if tau and Aβ are independently 
affected by trauma, blocking Aβ production should have no effects on tau pathology 
observed following TBI in these mice.   
We first confirmed that inhibition of γ-secretase blocked intra-axonal Aβ 
buildup in 3xTg-AD mice following moderate TBI. We treated injured mice with 
compound E (CmpE), a small molecule inhibitor of γ-secretase (Seiffert et al., 2000; 
Olson et al., 2001; Grimwood et al., 2005; Yang et al., 2008; Yan et al., 2009)  or DMSO 
vehicle. Mice received i.p. injections of 10 mg/kg of CmpE or vehicle at 1 h before 
injury, then again at 5 h, 11 h, and 17 h post injury. The frequent dosing regimen was 
employed due to the short half-life of CmpE (Yan et al., 2009)). A relatively high dose 
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was used due to the presence of a PS1 mutation in 3xTg-AD mice, since such mutations 
may result in diminished response to γ-secretase inhibition (Czirr et al., 2007). 
 In our first experiment, mice were sacrificed at 24 h following injury. One 
group of CmpE and vehicle treated mice was used for immunohistochemical analysis, 
another group was used for biochemical assessment. For histology, we used polyclonal 
antibody Aβ40 for Aβ immunohistochemistry in this experiment since γ-secretase 
cleavage of APP is at the C-terminus of Aβ; N-terminal anti-Aβ antibodies would still 
recognize the longer APP fragments remaining after γ-secretase inhibition. We stained 
these brains for APP to assess the extent of axonal injury.  We also assessed full-length, 
α-CTFs and β-CTFs (APP fragments resulted from cleavage of APP by α- and β-
secretases respectively) in the cerebellar lysates of the same mice via western blot to 
demonstrate that CmpE was effective at inhibiting brain γ-secretase activity. For the 
biochemical assessment, we sacrificed mice by rapid decapitation and homogenized 
ipsilateral hippocampi in RIPA buffers. RIPA lysates of CmpE and vehicle treated mice 
were used to determine levels of Aβ40 by ELISA.  
CmpE treatment almost completely prevented intra-axonal Aβ accumulation in 
ipsilateral fimbria of injured 3xTg-AD mice (Figure 4.1 A-D). Stereological 
quantification of numbers of Aβ40-positive axonal varicosities showed ~90% reduction 
in CmpE vs. vehicle treated mice (Figure 4.1 E, 1-sided t-test, p < 0.0001). 
Biochemical quantification of RIPA-soluble Aβ40 in ipsilateral hippocampi and 
surrounding white matter showed similar reduction (Figure 4.1 F, 32.5 ± 2.87 pg/mg 
in CmpE treated mice vs. 217.9 ± 52.1 pg/mg in vehicle treated mice, 1-sided t-test, p 
= 0.0013).  
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Figure 4.1 Systemic inhibition of γ-secretase activity with Compound E (CmpE) 
blocked post-traumatic Aβ accumulation in moderately (2.0 mm) injured 3xTg-AD 
mice. 
A. Representative Aβ40 IHC for an injured 3xTg-AD mouse receiving CmpE treatment. Scale 
bar in A: 1 mm. B. Higher magnification image of the fimbria of a CmpE treated mouse (box in 
A). Scale bar in B: 50 µm. C. Representative Aβ40 IHC for an injured 3xTg-AD mouse receiving 
DMSO vehicle treatment. D. Higher magnification image of the fimbria of a vehicle treated 
mouse (box in C). E. Stereological quantification of numbers of Aβ40-stained varicosities in the 
ipsilateral fimbria of injured 3xTg-AD mice receiving either CmpE or vehicle treatment. *** p < 
0.0001, Student’s t-test. N=7-8 mice per group. F. RIPA-extracted Aβ40 levels in ipsilateral 
hippocampal tissues of injured 3xTg-AD mice receiving either CmpE or vehicle treatment. *** 
p = 0.001, Student’s t-test. N = 6-7 mice per group. These data demonstrated intra-axonal Aβ 
buildup following TBI could be inhibited by blocking γ-secrectase activity.   
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CmpE effectively blocked γ-secretase activity in the setting of TBI, as evidenced 
by similar levels of full-length APP but increased α-CTFs and β-CTFs in cerebellar 
lysates of mice with CmpE treatment (Figure 4.2 A-B). Furthermore, numbers of APP-
stained varicosities were similar between treatment groups (Figure 4.2 C-D). This 
finding demonstrated that γ-secretase inhibition by CmpE specifically reduced 
proteolytic Aβ production, rather than reducing Aβ pathology by affecting extent of 
axonal injury in these injured mice.  
 
 
Figure 4.2 Compound E treatment in moderately injured (2.0 mm) 3xTg-AD mice 
caused accumulation of α- and β- C-terminal fragments (CTFs) but did not alter the 
extent of axonal injury. 
A. Schematic of cleavage sites of full-length APP (APP-FL) by α-, β-, and γ-secretases to 
generate CTFs and Aβ. B. Western blot of APP-FL and CTFs from cerebellar lysates of injured 
mice treated with CompoundE (CmpE) or vehicle. Full-length APP levels were similar, but 
there were more CTFs in injured mice treated with CmpE than vehicle control. This 
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demonstrates systemic CmpE treatment can inhibit γ-secretase activity in the brain. C. APP 
immunohistochemistry of fimbria from injured 3xTg-AD mice treated with CmpE or vehicle. 
Scale bar: 50 µm. D. Stereological quantification of APP-positive axonal varicosities in ipsilateral 
fimbria of injured mice treated with CmpE or vehicle. Similar numbers of APP-positive axonal 
varicosities in the two groups indicate CmpE treatment successfully blocked Aβ formation by 
inhibiting γ-secretase activity, not by affecting the extent of axonal injury in these mice. N=7-8 
per group. Bars represent mean ± SEM. Student’s t-test, ns: not significant.    
 
In summary, systemic CmpE treatment effectively blocked post-traumatic Aβ 
accumulation in injured axons of 3xTg-AD mice without affecting severity of axonal 
injury. 
4.2.2 Effects of Acute γ-secretase Inhibition on Post-
traumatic Tau Pathology 
CmpE treatment had no effect on tau pathologies in 3xTg-AD mice sacrificed 
at 24 h after TBI, despite the 90% reduction in Aβ accumulation (Figure 4.3, 4.4). We 
assessed total and phosphorylated tau levels in injured 3xTg-AD mice treated with 
CmpE or vehicle. Specifically, we studied tau pathology histologically with polyclonal 
total tau antibody, phospho-S199 antibody against tau phosphorylated at S199, and 
PHF1 antibody against phosphorylated tau at S396 and S404. We also examined tau 
pathology biochemically via western blots using the AT8, AT100, and Tau46 antibodies. 
Finally, we investigated total and phospho-S199 levels by ELISA. All assessments were 
done in a blinded fashion.  
Using quantitative stereological methods as described above, we found that the 
numbers of total tau-positive puncta in the ipsilateral fimbria, the numbers of total tau-
stained somata in the ipsilateral amygdala, and total length density of tau-positive CA1 
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processes were not affected by CmpE treatment in injured 3xTg-AD mice (Figure 4.3 
A-I). Total tau levels in the ipsilateral hippocampal tissues of injured mice treated with 
CmpE were not statistically different from those of vehicle treated mice, as assessed by 
human tau ELISA (819.7 ± 99.38 pg/mg in CmpE treated mice vs. 796.6 ± 161.1 
pg/mg in vehicle treated mice, Student’s t test, p = 0.9). 
 
 
Figure 4.3 Systemic γ-secretase inhibition with CmpE did not affect total tau pathology 
in injured 3xTg-AD mice killed at 24 h post injury. 
Total tau staining using polyclonal tau antibody in the ipsilateral fimbria (A-B), ipsilateral 
amygdala (D-E), and contralateral CA1 (G-H) of mice treated with CmpE (A, D, G) or vehicle 
DMSO (B, E, H). Scale bar in A: 50 µm. Stereological quantifications revealed similar numbers 
of total tau-positive puncta in the fimbria (C), amygdala (F), and CA1 (I) of CmpE and vehicle 
treated mice. Student’s t-tests, n.s: not significant. N = 7-8 mice per group. Bars are means ± 
SEM. 
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The increases in tau phosphorylation following TBI were not affected by CmpE 
treatment. There were similar numbers of pS199- and PHF1-positive tau puncta in 
ipsilateral fimbria of injured mice treated with CmpE compared to vehicle treated mice 
(Figure 4.4 A-F). Phospho-tau S199 levels in ipsilateral hippocampi assessed by ELISA 
revealed similar levels in CmpE and vehicle treated mice (CmpE group: 61.1 ± 9.2 
pg/mg vs. vehicle group: 57.9 ± 13.9 pg/mg, Student’s t-test, p = 0.85). Ipsilateral 
hippocampi of CmpE and vehicle treated mice subjected to western blotting using AT8 
and AT100 antibodies also corroborated these findings (Figure 4.4 G-H). Tau 
pathologies in these experimental groups were qualitatively and quantitatively similar to 
those seen in the moderately injured mice that received neither vehicle nor CmpE 
(Figure 3.7, 3.8, 3.11). Thus, it was unlikely that there were any effects of DMSO 
vehicle treatment or the additional handling required for the injections.  
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Figure 4.4 Inhibition of post-traumatic Aβ accumulation did not affect tau 
phosphorylation in injured 3xTg-AD mice. 
Phospho-tau staining using antibodies against tau phosphorylated at S199 (pS199, A-B) and at 
S396 and S404 (PHF1, D-E) in the ipsilateral fimbria of CmpE and vehicle treated mice. 
Stereological quantification showed similar numbers of pS199- (C) and PHF1-positive puncta 
(F) in the fimbria of mice treated with CmpE and vehicle. Student’s t-tests, n.s: not significant. 
N = 7-8 mice per group. G-H. AT8 (G) and AT100 (H) western blots of ipsilateral 
hippocampal lysates of mice received CmpE or vehicle. No significant difference was observed. 
Student’s t-tests. N = 6-7 mice per group. Bars are means ± SEM. 
 
To summarize, tau pathology was unaltered in injured 3xTg-AD mice, even 
though more than 90% of post-traumatic Aβ pathology was blocked.  
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4.3 Effects of Subacute (7 d) γ-secretase 
Inhibition on Post-traumatic Aβ and Tau 
Abnormalities in 3xTg-AD mice 
4.3.1 Effects of Subacute γ-secretase Inhibition on Post-
traumatic Aβ Accumulation 
We examined the effects of CmpE or vehicle treatment on injured mice up to 7 
days post TBI. We chose this survival period because we found that both Aβ and tau 
abnormalities persisted in untreated, injured mice at 7 days post TBI, though to a lesser 
extent than those observed at 24 h following TBI. Mice received CmpE or vehicle 
injections 4 times in the first 24 hours as described above, then twice daily until they 
were sacrificed at 7 days post injury. We stained brain sections for Aβ40 and APP to 
assess the effects of CmpE treatment on Aβ accumulation.  
Extended CmpE treatment successfully blocked the accumulation of the Aβ in 
the ipsilateral fimbria/fornix of injured 3xTg-AD mice at 7 days (Figure 4.5 A-C, 1-
sided t-test, p = 0.001). In vehicle treated mice, there were still numerous Aβ positive 
(Figure 4.5 B) and APP positive (Figure 4.5 E) varicosities at 7 days, though the 
extent of staining was reduced compared to 24 h post TBI (Fig 4.1, 4.2). Similar to the 
acute CmpE treatment experiments, extended CmpE treatment did not alter the extent 
of axonal injury as assessed by numbers of APP-positive varicosities in the ipsilateral 
fimbria/fornix (Figure 4.5 D-F). 
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Figure 4.5 CmpE treatment for 7 d blocked post-traumatic Aβ accumulation but did not 
affect extent of axonal injury in injured 3xTg-AD mice. 
A-B. Aβ staining using Aβ40 antibody in the ipsilateral fimbria of injured mice treated with 
CmpE or vehicle. C. Stereological quantification showed significant reduction of Aβ40-positive 
varicosities in the fimbria of mice received extended CmpE treatment, as compared to vehicle. 
*** p < 0.0001, Studen’s t-test. D-E. APP staining in the ipsilateral fimbria. F. Stereological 
quantification showed similar APP-positive varicosities. N = 7 mice per group. Bars are mean ± 
SEM.  
 
In summary, extended CmpE treatment for 7 days blocked more than 70% of 
post-traumatic Aβ accumulation in 3xTg-AD mice, but did not affect the extent axonal 
injury. 
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4.3.2 Effects of Subacute γ-secretase Inhibition on Post-
traumatic Tau Pathology 
We next stained brains of CmpE and vehicle treated mice for total tau using 
polyclonal antibody (pAb), and phospho-tau using pS199 and PHF1 antibodies. Total 
tau immunoreactivity in the fimbria, amygdala and CA1 were not statistically different in 
mice received CmpE and vehicle for 7 days post injury (Figure 4.6 A-I). Importantly, 
tau phosphorylation at phospho-S199 and PHF1 epitopes was also unaffected following 
7 days of CmpE treatment (Figure 4.6 J-O). Thus, we did not observe a delayed effect 
of inhibition of Aβ accumulation on tau pathology after TBI. 
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Figure 4.6 Extended CmpE treatment did not affect tau pathology in injured 3xTg-AD 
mice. 
Total tau staining using polyclonal antibody (pAb) in the ipsilateral fimbria (A-B), ipsilateral 
amygdala (D-E), and contralateral CA1 (G-H) of mice treated with CmpE or vehicle for 7 d. 
Scale bar in A: 50 µm. C, F, I. Stereological quantifications showed similar levels of total tau 
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between treatment groups. Phospho-tau staining using pS199 antibody (J-K) and PHF1 
antibody (M-N) in the fimbria of mice treated with CmpE or vehicle for 7 d. L, O. 
Stereological quantifications showed similar levels of pS199- and PHF1-positive puncta in the 
fimbria of CmpE and vehicle treated mice. Student’s t-tests. N = 7 mice per group. Bars are 
mean ± SEM.  
 
In summary, inhibition of γ-secretase activity with CmpE successfully blocked 
post-traumatic Aβ generation and buildup in injured axons in 3xTg-AD mice but did 
not affect either local or distant tau immunoreactivity. This provides experimental 
evidence that post-traumatic acceleration of Aβ and tau pathologies occur 
independently in this animal model.  
4.4 Discussion of γ-secretase Inhibition in 
Injured 3xTg-AD Mice and the Utility and 
Limitations of This Experimental TBI 
model 
In summary, we found that systemic inhibition of γ-secretase activity by CmpE 
effectively blocked the post-traumatic Aβ accumulation in 3xTg-AD mice at both 24 h 
and 7 d post injury. However, Aβ blockade did not affect tau pathology accelerated by 
TBI at either time points.  
The subacute effects of TBI are evidenced in the persistent immunoreactivity of 
APP, Aβ, total and phospho-tau in injured 3xTg-AD mice sacrificed at 7 days post 
injury. However, there was less APP, Aβ, and total tau immunoreactivity at 7 days 
compared to 24 h following TBI, presumably due to progressive cell death and tissue 
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loss at the affected regions at the later time point. Interestingly, tau phosphorylation at 
phospho-S199 and PHF1 epitopes remained elevated at 7 days post injury. This 
suggests a possible role for pathological tau on longer-term outcomes following TBI in 
vivo.  
Importantly, inhibition of enzymatic activity of γ-secrectase, one of the 
canonical enzymes involved in cleaving APP to form Aβ under physiological conditions, 
almost completely eliminated post-traumatic Aβ aggregation in injured 3xTg-AD. 
However, accelerated tau abnormalities observed following trauma in these mice appear 
likely to be independent of Aβ, since inhibition of intra-axonal Aβ buildup did not alter 
tau pathology. These findings were consistent during the acute (24 h) as well as the 
subacute (7 d) periods following TBI. This demonstrates the utility of this controlled 
cortical impact 3xTg-AD model in the mechanistic investigation of the association 
between TBI and AD-related pathology.  
Taken together, these results support a causal relationship between TBI and 
acceleration of Aβ and tau pathologies. Our mouse model is the first small animal 
model of which we are aware which reliably and rapidly reproduces these key features of 
acute human post-TBI Aβ and tau pathologies. This could be due to a number of 
reasons. First, previous TBI models using transgenic mice only utilized those which 
overexpress either mutated forms of APP or tau, not both (Smith et al., 1998; Uryu et 
al., 2002; Yoshiyama et al., 2005). Second, 3xTG-AD mice also have a knock-in PS1 
mutation, which shifts Aβ accumulation to mostly intracellular (Mastrangelo and 
Bowers, 2008), and possibly increases tau phosphorylation (Baki et al., 2004; Dewachter 
et al., 2008). Furthermore, methodological differences between our stereotaxic 
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electromagnetically driven controlled cortical impact device-based protocol and 
previously used injury paradigms could have resulted in different distributions of axonal 
injury or other subtle differences in post-injury physiology.  
However, there are several limitations of our TBI model. First, this model 
produces a central contusion and pericontusional axonal injury. Humans often do 
sustain contusions with pericontusional axonal injury, but many injuries in humans are 
diffuse or multifocal. Nonetheless, axonal injury appears to be a virtually ubiquitous 
sequela of TBI (Adams, 1982; Gennarelli et al., 1982; Gennarelli, 1983; Adams et al., 
1984; Gennarelli, 1993; Blumbergs et al., 1994, 1995; Geddes et al., 2000) and many 
types of injuries in humans have been reported to result in Aβ and tau pathology 
(Roberts et al., 1991; Schmidt et al., 2001; Smith et al., 2003a; Smith et al., 2003c; 
Ikonomovic et al., 2004; Uryu et al., 2007; McKee et al., 2009). Injured axons appear to 
be a major source of Aβ following TBI in humans (Smith et al., 2003c; Ikonomovic et 
al., 2004; Uryu et al., 2007; Chen et al., 2009), pigs (Smith et al., 1999b; Chen et al., 
2004), rats (Pierce et al., 1996; Iwata et al., 2002), and now mice. Therefore, robust 
axonal injury and intra-axonal Aβ accumulation lends support to the validity of our 
model. An additional mouse injury paradigm such as fluid percussion or impact 
acceleration injury that produces more diffuse axonal injury will be required in order to 
generalize our findings.  
Second, most humans with TBI do not have a known genetic predisposition to 
developing AD-related pathologies, while the 3xTg-AD line has 3 mutations implicated 
in familial dementia. This limitation applies to this and other mouse models of age-
related AD pathology as well. The introduction of these mutations seems to be required 
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either because of fundamental differences between mouse and human coding 
sequences, differences in gene regulation, the short life span of the mouse, or a 
combination of these. Mice with human wild-type APP, PS1 and tau alleles “knocked 
in” to the mouse loci would be useful to differentiate these possibilities.  
Third, while axonal tau accumulation has been observed in a few cases of acute 
TBI in humans, the effects of injury severity on axonal tau accumulation, as described in 
this study, have not been documented. Likewise, the increased somatic tau accumulation 
in this model is rarely observed in human TBI (Ikonomovic et al., 2004). Thus, the 
relevance of these pathologies is not known.  
Fourth, neither this animal model, nor any other small animal of which we are 
aware, develops acute post-traumatic extracellular Aβ plaque pathology. The relative 
importance of extracellular vs. intracellular Aβ pathologies in the setting of TBI is not 
known. Nonetheless, the opportunity to investigate one form of acute post-traumatic 
Aβ pathology, acute post-traumatic tau abnormalities, and the interaction of these two 
pathologies makes the model presented here a significant advance. Ultimately, full 
validation will require predictions made based on the model that are subsequently 
confirmed in humans. 
The question of whether these pathologies trigger chronic, progressive 
neurodegeneration remains to be addressed. Similarly, future studies should be 
performed to determine if these Aβ and tau abnormalities adversely affect behavioral 
outcomes in 3xTg-AD mice subjected to TBI.  If so, preclinical therapeutic trials would 
be required to determine whether clinically realistic interventions could ameliorate these 
deficits (Abrahamson et al., 2006; Loane et al., 2009). The long-term goal would be to 
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develop treatments that block the adverse effects of AD-related pathophysiological 
processes after acute TBI in humans.  
Based on our findings, it is most likely that Aβ does not play a critical role in 
TBI-induced tau pathology. However, a small fraction of Aβ remained following γ-
secrectase inhibition in injured 3xTg-AD mice. Thus, there may be minor yet toxic Aβ 
species which could ultimately affect tau pathology. Additional studies should be carried 
out to identify if such species exist and if they do in fact accelerate tau pathology in the 
setting of TBI. Experiments involving TauP301L only transgenic mice or 3xTg-AD, 
BACE -/- mice subjected to TBI would provide further insights into effects of TBI on 
tau pathology. If, as seems likely, tau pathology is truly independent of Aβ in the setting 
of TBI, the underlying mechanisms will require investigation in order to elucidate 
additional therapeutic targets. Possible involvement of GSK3β, calpain, JNK and cdk5 
cascades on tau pathology could be considered (Querfurth and LaFerla, 2010).  
Apart from its effects on Aβ production, mutant PS1 has been implicated in 
other functions such as neuronal calcium dyshomeostasis and regulation of synaptic 
plasticity (Thinakaran and Parent, 2004; Mattson, 2010). Since dysregulation of calcium 
signaling is thought to play an important role in glutamate-induced excitotoxicity 
following brain injury (Tymianski and Tator, 1996; Arundine and Tymianski, 2004; 
Szydlowska and Tymianski, 2010), it is possible that the mutant PS1 in the 3xTg-AD 
mouse model may exacerbate TBI-induced neurodegeneration, in addition to its effects 
on both Aβ and tau pathologies. Future experiments subjecting PS1 single transgenic 
mouse to brain trauma will be required to elucidate its role in the context of TBI.  
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In conclusion, this controlled cortical impact model using 3xTg-AD mice 
reproduced key features of human post-TBI AD-related pathology. It will likely allow 
many mechanistic hypotheses to be tested and may be useful for preclinical therapeutic 
development.   
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Chapter 5 
Aβ Pathology in APP/PS1 and Tau 
Pathology in TauP301L Mice following 
TBI 
5.1 Introduction 
To test whether the findings in 3xTg-AD mice can be generalized, we subjected 
two additional transgenic mouse lines to controlled cortical impact TBI. We found that 
TBI caused acute Aβ accumulation in young APP/PS1 mice (Jankowsky et al., 2004), 
which harbor a different PS1 mutation from 3xTg-AD mice. Furthermore, TBI acutely 
accelerated tau pathology in TauP301L transgenic mice (Gotz et al., 2001). Overall, our 
TBI models represent a useful tool for future investigation into the link between TBI 
and AD.  
5.2 Axonal Aβ Pathology in Young APP/PS1 
Mice at 24 h Post Injury 
To test whether the findings of acute Aβ accumulation post TBI in 3xTg-AD 
mice can be generalized to another mouse model, we subjected a different transgenic 
line, APP/PS1 mice to experimental TBI of similar injury severity. These mice 
overexpress the Swedish (K670M/N671L) mutation of the human APP gene and the 
human PS1 gene with exon 9 deleted (Jankowsky et al., 2004). They were injured at 2 
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months of age; extensive extracellular Aβ pathology normally develops by 
approximately 6 months of age in this line. They were sacrificed at 24 h post TBI; their 
brains were stained for APP to assess the extent of axonal injury, and for Aβ using both 
panAβ and HJ3.4 antibodies. TBI resulted in comparable degree of axonal injury in 
pericontusional white matter in both APP/PS1 and 3xTg-AD mice, as evidenced by 
similar patterns of APP staining (Figure 5.1 B-C). Stereological quantification of APP-
positive axonal varicosities corroborated the qualitative observation (3xTg-AD: 295,579 
± 36,388 APP-positive axonal varicosities per cubic mm, n = 8 vs. APP/PS1: 272,212 ± 
43,249, n = 5, p = 0.69). Likewise, the pattern of Aβ accumulation detected by panAβ 
and HJ3.4 antibodies appeared similar in injured 3xTg-AD and APP/PS1 mice (Figure 
5.1 E-F, H-I). Quantification also confirmed this histological finding (3xTg-AD: 65,437 
± 8,458 HJ3.4-positive varicosities vs. APP/PS1: 47,257 ± 11,763, p = 0.23). Uninjured 
APP/PS1 mice at 2 months of age had neither APP nor Aβ accumulation in the 
ipsilateral fimbria/fornix (Figure 5.1 A, D, G).  
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Figure 5.1 Aβ accumulated in fimbria/fornix axons of 2 month-old APP/PS1 mice at 24 
hours post TBI. 
A-C. APP staining in the ipsilateral fimbria/fornix of a sham APP/PS1 mouse (A), an injured 
APP/PS1 mouse (B), and an injured 3xTg-AD mouse (C). Scale bar: 50 µm. Similar extent of 
axonal injury as detected by APP staining was seen in injured APP/PS1 and 3xTg-AD mice. D-
F. Aβ staining with panAβ antibody. G-I. Aβ staining with HJ3.4 antibody. Histological and 
stereological quantification showed similar extent of Aβ accumulation in injured APP/PS1 and 
3xTg-AD mice: 47,257 ± 11,763 HJ3.4-positive varicosities per cubic mm in APP/PS1 (n = 5) 
vs. 65,437 ± 8,458 in 3xTg-AD mice (n = 8), Student’s t-test, p = 0.23. 
 
These data suggest post-traumatic Aβ accumulation in 3xTg-AD mice is not 
unique to the genetic constructs carried by these mice.   
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5.3 Tau Pathology at 24 h following TBI in 
Single Transgenic TauP301L Mice 
To provide further evidence for the independent relationship between Aβ and 
tau in the setting of TBI, we performed controlled cortical impact TBI on transgenic 
mice expressing only human tau mutant gene, TauP301L (Gotz et al., 2001). Expression of 
the transgene in these mice was under transcriptional control of the Thy1.2 promoter, 
the same promoter which drives transgenes expression in 3xTg-AD mice. Tau 
pathology was investigated at 24 h post TBI in 6 month old TauP301L mice by 
immunohistochemistry with an antibody against total human tau. We found that 
controlled cortical impact TBI also caused acute tau accumulations with punctate 
morphologies in the ipsilateral fimbria/fornix of injured TauP301L mice (Figure 5.2 A-B). 
Quantification indicated there were substantial numbers of tau-positive puncta in the 
ipsilateral fimbria/fornix of injured TauP30L mice; approximately half as many as in 
injured 3xTg-AD mice (TauP301L: 63,180 ± 9,636 tau-positive puncta per cubic mm of 
fimbria, n = 6, vs. 3xTg-AD mice: 138,887 ± 35,543, n = 8, p = 0.1). This result is not 
surprising, as the 3xTg-AD mice were homozygous for human mutant tau whereas the 
TauP301L mice were heterozygous. Furthermore, total tau staining in the ipsilateral 
amygdala and contralateral CA1 of injured TauP301L was increased relative to sham 
TauP301L mice, similar to the effects in injured 3xTg-AD mice (Figure 5.2 C-F vs. 
Figure 3.8). 
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Figure 5.2 TBI acutely accelerated tau pathology in TauP301L mice. 
A-B. Punctate total tau staining (pAb) in the ipsilateral fimbria of injured but not sham TauP301L 
mice. Scale bar in A: 50 µm. Stereological quantification showed similar numbers of tau-positive 
puncta in this region in TauP301L and 3xTg-AD mice: TauP301L: 63,180 ± 9,636 tau-positive 
puncta per cubic mm of fimbria, n = 6, vs. 3xTg-AD mice: 138,887 ± 35,543, n = 8, Student’s 
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t-test, p = 0.1. C-D. Increased tau immunoreactivity in the cell bodies of the ipsilateral amygdala 
of injured compared to sham TauP301L mice. E-F. Increased tau immunoreactivity in processes 
of the contralateral CA1 of injured compared to sham TauP301L mice. G-H. Phospho-tau 
staining using pS199 antibody against tau phosphorylated at S199. I-J. Phospho-tau staining 
using PHF1 antibody against tau phosphorylated at S396 and S404. Both phospho-tau 
antibodies detect punctate axonal tau accumulations in the ipsilateral fimbria of injured but not 
sham TauP301L mice.  
 
Since TBI acutely affects tau phosphorylation in 3xTg-AD mice at several sites 
(Chapter 3.3), we tested whether TBI increased tau phosphorylation in injured TauP301L 
mice by staining with antibodies against tau phosphorylated at S199 (pS199) and at S396 
and S404 (PHF1). Abnormal, punctate phospho-tau staining was observed in the 
ipsilateral fimbria/fornix of injured but not uninjured TauP301L mice (Figure 5.2 G-J). 
Similar results were found in all 6 injured TauP301L mice. 
In summary, controlled cortical impact TBI consistently increased tau pathology 
in both young 3xTg-AD mice and TauP301L mice. The spatial and temporal pattern of tau 
pathology was distinct from that of Aβ. 
 
5.4 Discussions of Findings in APP/PS1 and 
TauP301L Mice 
In summary, we showed that the finding of post-traumatic Aβ accumulation in 
3xTg-AD mice was recapitulated in a different transgenic mouse model of Alzheimer’s 
disease, APP/PS1. Furthermore, accelerated tau pathology was also observed in 
transgenic mice carrying only TauP301L mutation at 24 hours following TBI. 
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We have previously presented evidence that TBI can independently alter Aβ and 
tau abnormalities in 3xTg-AD mice (Chapter 4). Specifically, systemic inhibition of γ-
secretase activity, an enzyme required for Aβ generation from its precursor, APP, 
successfully blocked post-traumatic Aβ accumulation in injured mice. However, tau 
pathology was unaffected following blockade of Aβ generation and accumulation. The 
finding that TBI can accelerate tau pathology in single transgenic TauP301L mice further 
supports the hypothesis that Aβ and tau pathologies are independent in the setting of 
TBI. As such, future studies will be required to investigate the mechanisms underlying 
TBI-induced tau hyperphosphorylation.  
PS1 mutations are thought to drive intracellular Aβ generation (Chui et al., 
1999). Additionally, transgenic mice which have both PS1 mutations and APP 
mutations exhibit accelerated Aβ pathology compared to those with only APP 
mutations (Borchelt et al., 1997; Holcomb et al., 1998; Wirths et al., 2001; Blanchard et 
al., 2003; Jankowsky et al., 2004; Wirths et al., 2006). In the setting of TBI, these 
mutations also appear necessary for rapid intra-axonal Aβ accumulations. Acute Aβ 
accumulation in axons of injured 3xTg-AD and APP/PS1 mice in the present study and 
the lack of such pathology in previous experimental TBI models using wildtype and 
mutant APP mice without PS1 mutations support this observation (Johnson et al., 
2010).   
However, our TBI mouse models have several limitations. First, we utilized 
transgenic mice with mutations implicated in familial dementia, while most human with 
TBI are not genetically predisposed to developing such Aβ and tau pathologies. 
Nevertheless, these mutations seem to be required for post-traumatic human 
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pathologies to be recapitulated in mice. Other genetic differences between human and 
mice may be one of the underlying reasons. Second, the majority of brain injuries in 
human are mild and diffuse (Cassidy et al., 2004), while our TBI model produces a 
relatively severe, focal contusion with pericontusional axonal injury. Thus, to generalize 
our findings, other TBI paradigms such as fluid percussion injury and closed-skull 
impact, which result in more diffuse axonal injury, will be required. Lastly, the current 
study focuses only on the acute period post injury. Future studies will therefore be 
required to assess the long-term effects of intra-axonal buildup of Aβ and tau on 
neuronal survival, synaptic integrity, and behavioral outcomes following TBI in these 
mice.  
In summary, our experimental TBI model using 3xTg-AD, APP/PS1, and 
TauP301L mice confirms the causal role of TBI in acceleration of acute Alzheimer-related 
pathological abnormalities. These models may provide useful tools to study therapeutic 
strategies to prevent adverse effects mediated by these pathologies following brain 
injury. 
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Chapter 6 
Investigation of  Potential Mechanisms 
underlying TBI-induced Tau 
Hyperphosphorylation 
6.1 Introduction 
Progressive accumulation of hyperphosphorylated microtubule-associated 
protein tau into neurofibriallry tangles (NFTs) and neuropil threads is a common 
feature of many neurodegenerative tauopathies, including Alzheimer’s disease (AD) and 
frontal temporal lobar degeneration (FLTD) (Ballatore et al., 2007). Tau pathology has 
also been documented in individuals who suffered from a single severe traumatic brain 
injury (TBI) or multiple mild, concussive injuries (Ikonomovic et al., 2004; Uryu et al., 
2007; McKee et al., 2009; Johnson et al., 2011). Tau pathologies in AD and TBI share 
similar immunohistochemical and biochemical features (Tokuda et al., 1991; Schmidt et 
al., 2001). In both conditions, somatodendritic tau immunoreactivity is prominent, 
However, tau-immunoreactive neurites observed in TBI have been suggested to have an 
axonal origin, which may be distinct from the threadlike forms in AD suggested to be 
dendritic in origin (Tokuda et al., 1991; Braak et al., 1994; Anderton et al., 1998; 
Ikonomovic et al., 2004; Uryu et al., 2007; McKee et al., 2009). Furthermore, the 
anatomical distribution of NFTs may be different following TBI than is typically seen in 
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AD (McKee et al., 2009). As such, the exact mechanisms leading to tau 
hyperphosphorylation in TBI may differ from those in AD.  
Multiple studies suggest tau pathology results in part from loss-of-function of 
tau (Ballatore et al., 2007). Abnormally phosphorylated tau has reduced microtubule 
(MT) binding, which result in MT destabilization. This compromises normal 
cytoskeletal function, ultimately leading to axonal- and neuronal- degeneration 
(Bramblett et al., 1993; Alonso et al., 1994; Merrick et al., 1997). Two major 
mechanisms proposed to underlie tau hyperphosphorylation are aberrant activation of 
kinases and downregulation of protein phosphatases. Cyclin-dependent kinase-5 
(CDK5) and its co-activator p25 (Patrick et al., 1999; Tseng et al., 2002; Noble et al., 
2003), glycogen synthase kinase-3β (GSK-3β) (Lucas et al., 2001; Hernandez et al., 
2002), and protein phosphatase 2A (Gong et al., 1993; Gong et al., 1995; Kins et al., 
2001) have been implicated in hyperphosphorylation of tau in vivo. Others such as 
protein kinase A (PKA)(Litersky and Johnson, 1992; Wang et al., 2007), extracellular 
signal-regulated kinase 1/2 (ERK1/2) (Drewes et al., 1992; Goedert et al., 1992), and c-
jun N-terminal kinase (JNK) (Goedert et al., 1997; Buee-Scherrer and Goedert, 2002; 
Yoshida et al., 2004; Vogel et al., 2009) have only been shown to regulate tau 
phosphorylation in vitro. It is unknown whether these kinases and phosphatase 
contribute to TBI-induced tau pathology. 
We have previously reported that controlled cortical impact TBI accelerated tau 
pathology in young 3xTg-AD and TauP301L mice (Tran et al., 2011). Importantly, the 
post-traumatic tau pathology appeared to be independent of Aβ. Furthermore, TBI-
induced tauopathy in these mice resembled tau pathology observed in humans in that 
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tau immunoreactivity was evident in both axonal and somatodendritic compartments. In 
this study, we used these experimental TBI mouse models to investigate mechanisms 
responsible for increased tau phosphorylation following brain trauma. We found JNK 
to be critically involved in this process. This suggests targeting JNK pathway may be 
beneficial in amelioration adverse effects of tau pathology in the setting of TBI.  
6.2 Examination of Various Kinase and 
Phosphatase Activities in Hippocampal 
Homogenates of TBI and Sham 3xTg-AD 
Mice at 24 h 
Aberrant activation of tau kinase(s) (Patrick et al., 1999; Lucas et al., 2001; 
Hernandez et al., 2002; Tseng et al., 2002; Cruz et al., 2003; Noble et al., 2003) or 
inhibition of protein phosphatases (Gong et al., 1993; Gong et al., 1995; Arendt et al., 
1998; Kins et al., 2001) are the major proposed mechanisms underlying tau 
hyperphosphorylation in many tauopathies. We therefore tested whether these 
mechanisms could account for the observed trauma-induced tau phosphorylation in our 
experimental TBI model. Toward this end, we subjected young 3xTg-AD mice to sham 
or controlled cortical impact TBI. After 24 hours, ipsilateral hippocampi and 
surrounding white matter, including the fimbria/fornix, were dissected, immediately 
frozen, and homogenized in RIPA buffer. We studied overall tissue levels of the 
following tau kinases via western blots: protein kinase A (PKA), extracellular signal-
regulated kinase 1 and 2 (ERK1/2), glycogen synthase kinase-3β (GSK-3β), and the 
stress activated kinase, c-jun N-terminal kinase (JNK) (Drewes et al., 1992; Goedert et 
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al., 1992; Robertson et al., 1993; Sperber et al., 1995; Litersky et al., 1996; Goedert et al., 
1997; Buee-Scherrer and Goedert, 2002; Yoshida et al., 2004; Virdee et al., 2007). 
Phosphorylation of the catalytic subunit of PKA is essential for its activity (Adams et al., 
1995; Smith et al., 1999a), while ERK1/2 and JNK are activated via phosphorylation 
(Anderson et al., 1990; Lisnock et al., 2000; Wada et al., 2001). Thus, blots were probed 
with phospho-specific antibodies to assess the levels of active PKA, ERK1/2, and JNK 
(Figure 6.1 A). GSK-3β activity, on the other hand, is controlled via inhibitory 
phosphorylation of GSK-3β at Ser-9 by Akt/protein kinase B pathways (Cross et al., 
1995). Thus, blots were probed with an antibody against phosphorylated Ser-9 of GSK-
3β (Figure 6.1 A). Another well-characterized tau kinase is the cyclin-dependent kinase 
5 (CDK5). Physiological activity of CDK5 is regulated by its association to the 
regulatory subunit p35, while association of CDK5 to p25 results in abnormal kinase 
activation and contributes to neurodegeneration (Patrick et al., 1999; Cruz et al., 2003; 
Noble et al., 2003). Therefore, we also measured CDK5, p35, and p25 levels via western 
blot to probe for CDK5 activity following TBI (Figure 6.1 C). Western blot analyses 
showed no difference in the total and activated levels of all examined kinases from the 
homogenates of TBI compared to sham mice (p > 0.05, Figure 6.1 B, D).  
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Figure 6.1 TBI did not affect hippocampal levels of tau kinases and activities of tau 
phosphatases at 24 h. 
A. Representative western blots of ipsilateral hippocampal lysates of a sham and an injured 
(TBI) mouse detected with antibodies against phosphorylated PKA (p-PKA), p-ERK1/2, p-
GSK3β at Ser9, and p-JNK. Blots were stripped and reprobed with antibodies against total 
PKA, ERK1/2, GSK3β, and JNK. The same blots were finally stripped and reprobed with α-
tubulin for loading control. B. Densitometric quantification of ratios of phosphorylated protein 
over total protein of each examined kinase from hippocampal lysates of TBI mice, expressed as 
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% of sham. None were significantly different from 100%. C. Representative western blots of 
ipsilateral hippocampal lysates of a sham and a TBI mouse probed with antibodies against total 
CDK5 and its regulatory subunits, p35/p25. CDK5 blots were reprobed with α-tubulin for 
loading control. D. Densitometric quantification of bands immunoreactive for CD5, p35, and 
p25 from hippocampal lysates of TBI mice, expressed as % sham. No significant difference was 
observed between TBI (n = 4) and sham (n = 4) samples, Student’s t-test.  E. Activity of 
protein phosphatase 2A (PP2A) and 2B (PP2B, calcineurin) from hippocampal lysates of TBI 
mice, expressed as % sham. No significant difference was observed between TBI (n = 6) and 
sham (n = 6) samples, Student’s t-test. 
 
Protein phosphatase 2A (PP2A) and protein phosphatase 2B (PP2B) are two 
major tau phosphatases (Gong et al., 1995; Wang et al., 1995; Gong et al., 2000). Thus, 
we measured the activities of these phosphatases from the same hippocampal 
homogenates of TBI and sham mice using a phosphatase activity assay kit. We found 
that TBI did not significantly affect activities of PP2A and PP2B when compared to 
sham mice (p > 0.05, Figure 6.1 E).  
To summarize, changes in tau kinases and phosphatases could not be detected 
at the whole tissue homogenate level 24 h following injury in 3xTg-AD mice. 
6.3 Immunohistochemical Analyses of 
Activated Kinases in Injured and Sham 
3xTg-AD Mice at 24 h 
Traumatic axonal injury (TAI) is a prominent feature of TBI in many contexts 
(Gennarelli et al., 1982; Gentleman et al., 1995; Geddes et al., 2000; Smith et al., 2003b), 
including pericontusional axonal injury in our mouse model (Tran et al., 2011). TAI is 
thought to disrupt axonal transport and therefore alter the localizations of many 
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proteins (Povlishock and Christman, 1995). As such, it is probable that TAI causes 
mislocalizations of tau and tau kinases, resulting in the observed TBI-induced tauopathy 
in our model. We tested this hypothesis by subjecting separate 3xTg-AD mice to TBI or 
sham injuries, and examining their brains immunohistochemically. We stained their 
brains for activated forms of PKA, ERK1/2, and JNK, and for total CDK5 using the 
same antibodies used for western blotting. In a pilot experiment, we did not observe any 
immunoreactivity in our tissues using antibody directed against phospho-S9 of GSK-3β 
(not shown). Therefore, we used an antibody against phosphorylated tyrosine residues 
of GSK-3 in this experiment; tyrosine phosphorylation of GSK-3 is necessary for its 
functional activity and is enhanced following various insults (Hughes et al., 1993; Bhat 
et al., 2000; Leroy et al., 2002).  
We found that TBI resulted in activation of most of the kinases examined, 
primarily in injured axons of the ipsilateral fimbria/fornix (Figure 6.2). JNK (Figure 
6.2 K-L) appeared markedly activated compared to the rest of the examined kinases 
(Figure 6.2 A-J). JNK activation was also observed in the ipsilateral cortex and 
thalamus of injured mice (Figure 6.3 A-D), while increased immunoreactivity for 
activated PKA and GSK-3 was observed in the ipsilateral CA1 (Figure 6.3 E-H).   
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Figure 6.2 JNK was markedly activated in the ipsilateral fimbria/fornix of injured 3xTg-
AD mice and colocalized with phospho-tau. 
Representative brain sections from a sham and a TBI mouse stained with p-PKA (A-B), p-
ERK1/2 (C-D), CDK5 (E-F), p-GSK3 at Y279 and Y216 (G-H), and p-JNK (I-J). Scale bar in 
A: 50 µm. K. Percentage of fimbria area occupied by p-PKA, p-PKC, p-ERK1/2, CDK5, p-
GSK3, and p-JNK staining. Areas occupied by p-GSK3 and p-JNK were significantly different 
from sham. * p < 0.05, *** p < 0.001, Student’s t-test. p-JNK-positive area was significantly 
more than the rest of the examined kinases. # p < 0.0001, One-way ANOVA with Neuman 
Keuls post-test.  N = 4 mice per group. L-M. Colocalization of tau phosphorylated at S199 
(pS199) and phosphorylated JNK (p-JNK) in a TBI (M) but not sham (L) mouse.  
 
Densitometric analyses showed 7.6 ± 0.8% area with p-JNK-positive staining 
and 2.5 ± 0.5% area with p-GSK-3 in the fimbria/fornix of TBI mice vs. 0.38 ± 0.1% 
area in sham mice. Areas covered by p-JNK (p < 0.0001) and p-GSK-3 (p < 0.05) were 
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significantly greater in TBI compared to sham mice (Figure 6.2 M). In comparisons 
with other examined kinases, p-JNK staining in the fimbria/fornix was the most 
prominent (p < 0.0001, Neuman Keuls post-test following one-way ANOVA). 
Furthermore, double immunofluorescence and confocal microscopy revealed that p-
JNK colocalized with tau phosphorylated at Ser-199 (pS199) in the fimbria/fornix of 
injured but not sham mice (Figure 6.2 N-O).  
 
 
Figure 6.3 Activated JNK, PKA, and GSK-3 localized in distinct brain regions of injured 
3xTg-AD mice at 24 h. 
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A-D. Phopho-JNK staining (p-JNK) for activated JNK was observed in the ipsilateral cortex 
(B) and thalamus (D) of injured but not sham 3xTg-AD mice (A, C). Scale bars in A and C: 500 
µm. Insets in A-D: Higher magnification of p-JNK staining. Scale bar: 50 µm. E-F. Phospho-
PKA (p-PKA) for activated PKA. G-H. Phospho-GSK3 (p-GSK3) for activated GSK-3 in 
ipsilateral CA1 of injured 3xTg-AD mice. Scale bar in C: 50 µm.  
 
Taken together, these data suggest that mislocalizations of tau and tau kinases, 
particularly JNK, following TBI may be responsible for post-traumatic axonal tau 
pathology in 3xTg-AD mice.  
6.4 JNK Inhibition by D-JNKi1 Peptide in 
3xTg-AD and TauP301L Mice following 
controlled cortical impact TBI 
6.4.1 D-JNKi1 Peptide (5 µg) Inhibited JNK Activity and 
Reduced TBI-induced Tauopathy in 3xTg-AD mice 
 
To test the hypothesis that JNK is involved in increasing axonal tau 
phosphorylation and accumulation following TBI in 3xTg-AD mice, we treated mice 
with a specific peptide inhibitor of JNK, D-JNKi1, or control peptide, D-TAT via i.c.v 
injection immediately following TBI. D-JNKi1 was chosen over an alternative, the 
ATP-competitive inhibitor of JNK, SP600125, because of its high specificity to JNK 
and its long half-life (Bonny et al., 2001; Borsello et al., 2003b). We sacrificed mice at 24 
h post injury and examined their brains immunohistochemically. Since c-jun is a major 
target of JNK (Hibi et al., 1993), we stained for c-jun phosphorylated at Ser-63 (p-c-jun) 
to determine the extent to which JNK activity was inhibited by D-JNKi1 treatment. 
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TBI resulted in c-jun activation in many pericontusional regions, most consistently the 
ipsilateral thalamus (Figure 6.4 A-D). We therefore quantified p-c-jun nuclear staining 
in this region, and found that D-JNKi1 treatment reduced p-c-jun immunoreactivity 
approximately 40% when compared with D-TAT treated mice (p < 0.0001, Figure 6.5 
A-C).  
                                                                                                 
 
 
Figure 6.4 TBI caused c-jun activation in the ipsilateral cortex and thalamus of 3xTg-
AD mice. 
A-D. Phospho-cjun staining against activated cjun in the cortex and thalamus of injured mice. 
Scale bars: 500 µm. Insets: Higher magnification of nuclear c-jun staining. Scale bar: 50 µm. 
 
APP is a robust marker of axonal injury (Sherriff et al., 1994b; Graham et al., 
1995; Stone et al., 2000, 2001). Thus, we stained these brains for APP to assess the 
effects of JNK inhibition on the extent of axonal injury.  We also stained for APP 
proteolytic product, Aβ using the 3D6 antibody, which does not recognize APP 
(Johnson-Wood et al., 1997). D-JNKi1 treatment did not significantly affect the degree 
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of axonal injury as determined by the numbers of APP-positive axonal varicosities in 
the fimbria/fornix (p = 0.31, Figure 6.5 D-F). D-JNKi1 treatment appeared to reduce 
the numbers of 3D6-positive varicosities in the fimbria, but the reduction did not reach 
statistical significance when compared to D-TAT treated mice (p = 0.07, Figure 6.5 G-
I). This finding is not surprising because D-JNKi1 has been shown to reduce Aβ 
production in vitro (Colombo et al., 2007).  
 
Figure 6.5 D-JNKi1 treatment blocked c-jun phosphorylation but did not affect axonal 
injury and Aβ accumulation in injured 3xTg-AD mice at 24 h. 
A-B. Nuclear staining of phosphorylated c-jun at S63 (p-cjun S63) in the thalamus of injured 
3xTg-AD mice received i.c.v. injection of D-JNKi1 and D-TAT control peptide. Scale bar in A: 
500 µm. Insets in A and B: Higher magnification of p-cjun S63 staining. Scale bar: 50 µm. C. 
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Percentage of area occupied by p-cjun S63 staining in D-JNKi1 and D-TAT treated mice. JNK 
inhibition by D-JNKi1 significantly reduced extent of c-jun phosphorylation in the thalamus of 
injured 3xTg-AD mice: 40% reduction, *** p < 0.001. D-E. APP staining in the ipsilateral 
fimbria of injured 3xTg-AD mice treated with D-JNKi1 or D-TAT. Scale bar in D: 50 µm. F. 
Stereological quantification showed similar numbers of APP-stained varicosities in mice treated 
with D-JNKi1 compared to D-TAT. G-H. Aβ staining using N-terminal antibody 3D6 in the 
ipsilateral fimbria of injured 3xTg-AD mice treated with D-JNKi1 or D-TAT. I. Stereological 
quantification showed a nonsignificant 20% reduction in the numbers of Aβ-stained axonal 
varicosities between groups. n.s: not significant. Student’s t-tests.  N = 8-9 mice per treatment 
group. Bars are mean ± SEM. 
 
Although our D-JNKi1 treatment regimen did not fully block c-jun 
phosphorylation, we nevertheless asked if partial JNK inhibition was sufficient to affect 
post-traumatic tau pathology in our TBI mouse model. We assessed total tau pathology 
by staining with a polyclonal antibody which recognizes tau independent of its 
phosphorylation state (Figure 6.6 A-B, D-E, G-H). Stereological quantification 
showed a moderate but significant reduction (35%) of total tau-positive puncta in the 
ipsilateral fimbria/fornix (p = 0.025, Figure 6.6 C). As controls, we also quantified total 
tau-positive somata in the ipsilateral amygdala and tau-positive neurites in the 
contralateral CA1. These two regions exhibited increased total tau immunoreactivity 
(Section 3.3, Figure 3.7 and 3.8) but lacked p-JNK staining following TBI (not 
shown). As expected, stereological quantifications showed similar numbers of tau-
positive somata and neurites in the amygdala and CA1 of D-JNKi1 and D-TAT treated 
mice (p > 0.05, Figure 6.6 F, I).  
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Figure 6.6 JNK inhibition by D-JNKi1 peptide reduced axonal tau accumulation but did 
not affect somatodendritic tau accumulation. 
Total tau staining using polyclonal antibody (pAb) in the ipsilateral fimbria (A-B), ipsilateral 
amygdala (D-E), and caontralateral CA1 (G-H) of mice received D-JNKi1 or D-TAT i.c.v 
injection. Scale bar in A: 50 µm. C, F, I. Stereological quantifications showed D-JNKi1 
treatment reduced axonal tau accumulation in the fimbria (C), but did not affect somatic tau 
staining in the amygdala (F) nor tau-positive process length in the CA1 region (I). * p < 0.025, 
n.s: not significant. Student’s t-tests. N = 8-9 mice per group. Bars are mean ± SEM. 
 
We next studied effects of JNK inhibition on tau phosphorylation using 
phospho-specific antibodies against tau phosphorylated at Ser-199 (pS199), Ser-396 and 
Ser-404 (PHF1), and Thr-231 (pT231) (Figure 6.7 A-B, D-E, G-H). There were also 
significant reductions of numbers of pS199-positive (55%, p < 0.0001, Figure 3.26 C) 
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and PHF1-positive (34%, p = 0.014, Figure 6.7 F) puncta in the ipsilateral 
fimbria/fornix of D-JNKi1 compared to D-TAT treated mice. Numbers of pT231-
positive puncta were not statistically different between treatment groups (p = 0.12, 
Figure 6.7 I). This is consistent with in vitro findings that JNK preferentially 
phosphorylates tau at Ser-199 and Ser-396, but not at Thr-231 (Reynolds et al., 1997). 
 
 
Figure 6.7 D-JNKi1 treatment reduced tau pathology in injured axons of 3xTg-AD mice. 
Phospho-tau staining using polyclonal antibodies against tau phosphorylated at S199 (pS199, A-
B), at S396 and S404 (PHF1, D-E), and T231 (pT231, G-H) in the ipsilateral fimbria/fornix of 
injured 3xTg-AD mice treated with D-JNKi1 or D-TAT peptide. C, F, I. Stereological 
quantification of pS199-, PHF1-, and pT213-tau puncta in the ipsilateral fimbria of injured mice 
treated with D-JNKi1 or D-TAT. D-JNKi1 treatment significantly reduced numbers of pS199- 
and PHF1-tau puncta but had no effect of pT231-tau puncta in the ipsilateral fimbria of injured 
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mice. * p < 0.025, ** p < 0.001, ns: not significant. 1-sided t-tests. N = 8-9 mice per treatment 
group. Bars are mean ± SEM.  
 
In summary, we found that moderate reduction of JNK activity could effectively 
block the axonal accumulations of total, pS199, and PHF1-tau in injured axons of 3xTg-
AD mice. 
6.4.2 Similar Dose of D-JNKi1 Peptide (5 µg) Was 
Ineffective in Blocking JNK Activity in injured 
TauP301L Mice 
Since TBI caused acute increase in tau phosphorylation and accumulation in 
young TauP301L mice at 24 hours (Chapter 5.3), we asked if JNK is also involved in TBI-
induced tau pathology in these mice. We thus treated injured TauP301L mice with similar 
dose (5 µM) of D-JNKi1 or D-TAT control peptide via i.c.v injection immediately 
following TBI. When we assessed phospho-c-jun staining in the thalamus, we did not 
observe an effect of D-JNKi1 treatment on c-jun phosphorylation (Figure 6.8).  
   111 
 
 
Figure 6.8 D-JNKi1 treatment failed to block c-jun phosphorylation in injured TauP301L 
mice at 24 hours. 
A-B. Representative photomicrographs showing p-c-jun S63 IHC in the ipsilateral thalamus of 
injured TauP301L mice which received i.c.v. injection of D-JNKi1 or D-TAT control peptides (5 
µM). Scale bar in A: 500 µm. C. Quantitative histochemical analysis showed similar levels of p-c-
jun S63 staining in the thalamus of treated mice. N = 5 mice per group. Student’s t-test. n.s: not 
significant. Bars are mean ± SEM.  
6.5 Discussion of Findings on JNK Inhibition 
The current section shows that TBI resulted in different regional patterns of 
activation of a number of tau kinases. The primary site of kinase activation and 
accumulation was within injured axons, particularly the ipsilateral fimbria/fornix. JNK 
was markedly activated in this region compared to the rest of the examined kinases. 
JNK was also activated in cortical and thalamic regions surrounding the impact site. 
Notably, JNK appeared to play a critical role in TBI-induced tau hyperphosphorylation, 
as activated JNK colocalized with phospho-tau, and inhibition of JNK activity reduced 
tau phosphorylation in injured axons. 
Traumatic axonal injury (TAI) is thought to cause axonal transport deficits, 
resulting accumulations of various organelles and proteins, including neurofilaments and 
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APP (Povlishock and Christman, 1995). Our data suggest that axonal transport deficits 
induced by TAI may be responsible for the accumulation and activation of the 
examined tau kinases and tau. The observations that sciatic nerve ligation resulted in 
accumulation of total and phosphorylated ERK1/2 and JNK (Averill et al., 2001; 
Reynolds et al., 2001; Middlemas et al., 2003) lend support to this hypothesis. 
Nonetheless, this hypothesis can be further tested by treatment of TBI mice with drugs 
that rescue or reduce transport deficits, such as the microtubule stabilizer epothilone D. 
Epothilone D has been shown to reduce fast axonal transport defects in CNS axons and 
lessen axonal degeneration in tau transgenic mice (Brunden et al., 2010b).  
The distinct spatial distributions of activated kinases, particularly JNK, GSK-3 
and PKA are indicative of the heterogeneous responses of different brain structures and 
cellular compartments to TBI. Such selective responses may be better documented 
using immunohistochemical techniques, and thus in part accounts for the mismatch 
between our immunohistochemical and western blotting data. Nevertheless, it is 
possible that our semiquantitative densitometric approach used to quantify the levels of 
total and activated protein kinases in hippocampal homogenates may not be sensitive 
enough to detect modest but functionally important changes. It is also likely that these 
kinases exhibit transient pattern of activation, which our analysis at 24 h post TBI failed 
to capture. In fact, a study using fluid percussion TBI in rats has reported that activated 
ERK1/2 and JNK in hippocampal lysates were evident within minutes but no longer 
detectable within hours post injury (Otani et al., 2002b). As such, a more thorough 
analysis in which mice are sacrificed at different time points post injury will be necessary 
to resolve the temporal profiles of activation of these kinases. 
   113 
 
Importantly, JNK activation has been documented in contusional TBI in human 
(Ortolano et al., 2009). This supports the validity of our TBI model. JNK was also 
reported to be activated in a number of studies using the fluid percussion TBI model in 
rats (Mori et al., 2002b; Otani et al., 2002a; Otani et al., 2002b; Raghupathi et al., 2003; 
Ortolano et al., 2009) . Together, these data suggest that JNK activation is a general 
response to brain trauma, which is consistent with the role of JNK in signalling stress 
signals (Kyriakis and Avruch, 2001). Furthermore, ours and findings from Raghupathi et 
al. suggest that JNK signalling is complex and may have distinct functions in somata vs. 
axons (Rapughathi et al., 2003). In support of this notion, many studies provide 
evidence for the unequivocal roles of JNK and c-jun activation in programmed cell 
death in neurons (Silva et al., 2005). Although JNK function in axons has gotten less 
attention, recent investigations implicate JNK in signaling axonal injury (Cavalli et al., 
2005) and in mediating axonal degeneration (Miller et al., 2009). Since 
hyperphosphorylated tau is associated with axon degeneration, our findings of JNK role 
in tau phosphorylation is in line with previous reports.   
Nonetheless, our study bears a number of limitations. First, we have not tested 
the therapeutic windows during which D-JNKi1 can be administered. Borsello et al. 
showed that D-JNKi1 treatment can have beneficial effects if given up to 6 hours 
following ischemic injury (Borsello et al., 2003). Meanwhile, findings from Miller et al. 
indicated that JNK inhibition within 3 hours following axotomy of dorsal roots 
ganglion axons can effectively block JNK-mediated axon degeneration (Miller et al., 
2009). The latter time window of JNK inhibition is perhaps more applicable to our 
model, since axonal injury is a major pathology observed following TBI. Second, we 
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have not systematically tested other doses and methods of delivery of this peptide 
inhibitor. This may in part explain the negative result we observed with D-JNKi1 
treatment in injured TauP301L mice. Third, we have yet to determine which JNK isoform 
is responsible for induction tau phopshoryalation post injury. JNK1-/-, JNK2-/- and 
JNK3-/- knockout mice subjected to similar injury paradigm will be useful for this 
purpose. Fourth, even though hyperphosphorylation of tau has been observed 
following a single severe injury in human, the majority of tauopathy appears to occur in 
individuals suffering from multiple concussions, which result in a condition known as 
dementia pugilistica or chronic traumatic encephalopathy. As such, it would be 
important to test the role of JNK in tau phosphorylation in a different injury paradigm 
which more closely resembles human cases. In fact, our recently developed repetitive 
closed-skull injury model (Shitaka et al., 2011) is a good candidate model. Fifth, 
although our study supports JNK activation as a probable mechanism underlying TBI-
induced tau pathology, we cannot rule out other mechanisms that may result in tau 
hyperphosphorylation, such as changes in tau conformation (Kanaan et al., 2011) and 
other post-translational modifications of tau (Min et al., 2010; Cohen et al., 2011). As 
such, future studies will be required to assess these alternative mechanisms.  
Additionally, roles of GSK-3 and PKA in tau phosphorylation will require 
further investigation, as activated forms of these kinases were found to localize in both 
axons and ipsilateral CA1 regions of injured mice. Interestingly, inhibition of GSK-3 
was recently found to protect dorsal ganglion root axons from degeneration following 
axotomy (Gerdts et al., 2011). Thus, it is possible that a combined therapy involving 
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JNK, GSK-3, and possibly PKA inhibition may be required to observe functional 
benefits of blocking tau hyperphosphorylation and axon degeneration.  
In summary, we identified JNK as a likely kinase that phosphorylates tau in vivo 
in the setting of TBI. We propose that targeting the JNK pathway should be tested 
extensively to determine whether this is beneficial in amelioration of deficits induced by 
TBI. 
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Chapter 7  
Long-term Behavioral and 
Neurodegenerative Consequences of  
Acute Post-traumatic Aβ and Tau 
Pathologies in 3xTg-AD Mice 
7.1 Introduction 
Traumatic brain injury (TBI) is a major environmental risk factor for subsequent 
development of dementia of the Alzheimer’s type (Mortimer et al., 1991; Nemetz et al., 
1999; Plassman et al., 2000; Fleminger et al., 2003). Pathological hallmarks of AD 
include extracellular plaques containing the amyloid-beta (Aβ) peptides and 
neurofibirllary tangles containing microtubule-associated tau protein. Studies from 
human TBI, experimental TBI models in pigs (Smith et al., 1999b; Chen et al., 2004), 
and rodents (Iwata et al., 2002; Tran et al., 2011) support the link between TBI and AD 
at the pathological level. For instance, acute depositions of Aβ in diffuse plaques and 
inside axons have been documented in approximately 30% human TBI cases (Roberts 
et al., 1991; Roberts et al., 1994; Uryu et al., 2007). Acute accumulations of total and 
hyperphosphorylated tau inside axons and neurites, and less frequently tangle pathology, 
have also been reported in these patients (Smith et al., 2003c; Ikonomovic et al., 2004; 
Uryu et al., 2007; Johnson et al., 2011). Experimental TBI in pigs readily reproduced 
pathological features observed post TBI in human (Smith et al., 1999b), while TBI in 
   117 
 
rats only recapitulated the intra-axonal Aβ accumulation aspect (Iwata et al., 2002). Our 
recently published TBI model using transgenic 3xTg-AD mice, which had mutant 
APPswe, TauP301L, and PS1M146V knock-in, displayed acute intra-axonal total and 
phosphorylated tau accumulation, in addition to axonal Aβ pathology (Tran et al., 2011).  
Taken together, these findings support the hypothesis that TBI is causally related to 
AD. The questions of whether these acute pathologies negatively contribute to long-
term neurodegenerative and behavioral deficits, act as a protective response, or play a 
neutral role following TBI remained to be studied. We therefore tested these hypotheses 
in this study. Furthermore, we sought to investigate the roles of mutant PS1M146V in TBI-
induced neurodegeneration. Mutant PS1 is not only known to affect Aβ generation and 
tau phosphorylation (Baki et al., 2004; Koo and Kopan, 2004; Dewachter et al., 2008), 
but is also thought to disrupt calcium homeostasis (Mattson et al., 2000; LaFerla, 2002; 
Mattson, 2010). As such, PS1 mutant alone can have detrimental effects on neuronal 
and behavioral outcomes following TBI.  Since differences in genetic background 
strains may influence behavioral performance (Owen et al., 1997; Holmes et al., 2002), 
we generated homozygous 3xTg and PS1M146V littermates and used them for all 
experiments in this study. 3xTg mice are homozygous for APPswe, TauP301L, and PS1M146V 
mutations, while PS1 mice are homozygous for only PS1M146V mutation.  We subjected 
young mice to controlled cortical impact TBI, tested them on the Morris water maze 
task at 1 month and 6 months post injury, and assessed their brains histologically. We 
found that the acute post-traumatic Aβ and tau pathologies played a neutral role in long-
term outcomes: TBI-induced degeneration and long-term cognitive deficits in injured 
mice were similar between genotypes. Furthermore, while persistent axonal Aβ 
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pathology was observed up to 6 months post injury in 3xTg-AD mice, chronically 
abnormal tau phosphorylation was a common feature in both injured 3xTg-AD and PS1 
mice. Taken together, our data demonstrate that TBI can initiate chronic 
neurodegenerative processes but that these processes do not appear to contribute 
negatively to behavioral outcomes in mice.   
 
7.2 Spatial Learning as Assessed by the 
Morris Water Maze Task in 3xTg and PS1 
Littermate Controls at 1 and 6 months 
post TBI  
To study the long-term neurodegenerative and behavioral consequences of the 
acute Aβ and tau pathologies observed in 3xTg mice post TBI and to investigate the 
roles of mutant PS1M146V in TBI-induced neurodegeneration, we performed controlled 
cortical impact TBI on 3xTg and PS1 littermates. 3xTg mice are homozygous for 
APPswe, TauP301L, and PS1M146V mutations, while PS1 mice are homozygous for only 
PS1M146V mutation. Mice were moderately injured at 2.0 mm below the dura, since this 
injury severity has been previously shown to result in robust and acute Aβ and tau 
abnormalities in young 3xTg mice (Tran et al., 2011).  
To test for learning and memory, we used the Morris water maze task. One 
sham and one TBI group were tested at 1 month post TBI or sham surgeries, while 
another TBI group was tested at 6 months post injury. Overall, injured PS1 and 3xTg 
mice were significantly impaired in this task. For escape latencies in the visible platform 
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testing at 1 month post injury, there were significant main effects of injury status (F = 
17.28, p = 0.00026, repeated measures ANOVA), day of testing (p < 0.00001), but no 
interaction between injury status and day of testing (p = 0.17). There were also 
significant main effects of genotype (F = 6.94, p = 0.01), in which 3xTg mice took 37% 
longer time to locate the visible platform than PS1 mice (14.57 ± 1.07 vs 10.61 ± 1.05 
seconds).  There was a significant interaction between genotype and day of training (p = 
0.0041): latencies on day 1, but not days 2-3, were longer in 3xTg mice than PS1 mice. 
However, there was no interaction between injury status and genotype and day of 
testing (p = 0.95).   
In the hidden platform testing, injured PS1 and 3xTg mice took longer time and 
swam longer distance than respective sham mice (Figure 7.1A-B). There were 
significant main effects of injury status (Figure 7.1A, F = 19.06, p < 0.00001), day of 
training (F = 11.31, p < 0.00001), but there was no interaction between injury status and 
day of training (p = 0.77). There were no effects of genotype (F = 0.04, p = 0.85), 
genotype x injury status (p = 0.76), nor day x genotype x injury status (p = 0.84). 
Performance of TBI mice at 1 month was equally impaired compared to 6 months post 
injury (p = 0.57). Similar results were found for escape distances, in that significant main 
effects were only observed for injury status (Figure 7.1B, F = 14.63, p = 0.00001). In 
pre-specified post hoc tests, mean escape time and escape distance over 4 days of 
training were not statistically different between injured PS1 and 3xTg mice at either 1 
month or 6 months post injury (Figure 7.1 C-D, p > 0.05, Dunn’s post hoc test). 
Injured mice at both time points performed worse than respective sham mice (p < 
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0.001). There was no difference in probe performance between injured and sham mice 
of either genotype at either time points (Figure 7.1E).  
In summary, TBI caused long-term cognitive deficits in PS1 and 3xTg 
littermates. The impairments in visible platform could result from reduced motivation, 
motor and visual dysfunctions, or a combination of these factors. Notably, expression 
of all 3 transgenes in 3xTg mice appears to influence their performance in this portion 
of the task. The longer time and distance injured mice took to reach the hidden 
platform are likely due to deficits in spatial learning. All mice performed well on the 
probe trial, though it is possibly due to overlearning. Most intriguingly, TBI negatively 
affected PS1 and 3xTg to the same extent.  
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Figure 7.1 Injured 3xTg and PS1 littermate controls were equally impaired in spatial 
learning at 1 and 6 months post TBI. 
A. Escape time mice took locate hidden platform by day of training. Repeated measures 
ANOVA. There is no statistical difference between genotype, genotype x injury status, day x 
genotype x injury status, p > 0.05. Statistical difference was only observed between injury status, 
*** p < 0.0001. B. Escape distance mice took to locate hidden platform. Statistical difference 
was only observed between injury status, ** p < 0.001. C. Mean time mice swam to find the 
   122 
 
hidden platform. Each data point represents average time of 4 trials per day, and over 4 days of 
training.  D. Mean distance mice swam to find the hidden platform. Each data point represents 
average time of 4 trials per day, and over 4 days of training. Kruskal-Wallis test with Dunn’s 
post-hoc test. Bars are mean ± SEM. E. Probe trial at 24 h post the last training session; bars 
are 95% CI.  
7.3 Neurodegeneration in 3xTg and PS1 
Littermate Controls at 1 and 6 months 
post TBI 
Following Morris water maze testing, all mice were sacrificed. Their brain 
sections were stained with cresyl violet for cytoarchitecture delineation. The remaining 
volumes of the hippocampus and fimbria ipsilateral to the injury site were quantified to 
determine the extent of degeneration following TBI. There were progressive atrophies 
of the ipsilateral hippocampus and fimbria of injured PS1 and 3xTg mice over time 
(Figure 7.2 A-F). Quantitative analyses corroborated the histological observations 
(Figure 7.2 G-H). Specifically, hippocampus and fimbria volumes of sham injured mice 
were significantly greater than those of injured mice (Figure 7.2 G-H, p < 0.0001). 
There were no significant difference in these measures between genotypes at 1 or 6 
months post TBI (Figure 7.2 G-H, p > 0.05, Dunn’s post hoc test). 
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Figure 7.2 Ipsilateral hippocampus and fimbria of PS1 and 3xTg-AD littermates 
atrophied at similar rates following TBI. 
Cresyl violet staining for cytoarchitechture. A-C. Representative photomicrographs of brains of 
PS1 mice sacrificed after sham surgery at 1 mo (A), and after TBI at 1 mo (B) and 6 mo (C).  
Scale bar: 2mm. D-F. 3xTg-AD mice. G. Quantification of the hippocampus volume of PS1 
and 3xTg-AD littermates subjected to sham or TBI and sacrificed at indicated time points. H. 
Quantification of the fimbria volume of PS1 and 3xTg-AD littermates subjected to sham or 
TBI and sacrificed at indicated time points. Kruskal-Wallis test with Dunn’s post-hoc test. ns: 
not significant. 
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7.4 Histopathologies of 3xTg and PS1 
Littermate Controls at 1 and 6 months 
post TBI 
7.4.1 Long-term Consequences of TBI on Axonal Injury 
and Axonal Aβ Pathology 
To assess the long-term effects of TBI on axonal injury, we stained brain 
sections of 4 randomly chosen mice in each group with APP, a robust marker of axonal 
injury. Since we have previously reported that the ipsilateral fimbria/fornix of injured 
3xTg mice exhibited extensive APP staining at 24 h and up to 7 d post TBI (Tran et al., 
2011), we focused on this pericontusional axonal tract for our chronic study. There 
were still numerous APP-stained axonal bulbs in the ipsilateral fimbria/fornix of injured 
mice at 1 mo post TBI (Figure 7.3 B, E, H). This staining persisted up to 6 months 
following injury, though to a lesser extent (Figure 7.3 C, F, I). APP axonal bulbs at 
these chronic time points still had the spheroidal morphology, which is typical of 
injured axons. As expected, axonal APP-stained varicosities were not observed in sham 
injured mice (Figure 7.3 A, D, G). Interestingly, the extent of APP staining was 
qualitatively similar in both injured PS1 and 3xTg littermates.  
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Figure 7.3 Persistent axonal injury as detected by APP immunohistochemistry in PS1 
and 3xTg littermates at 1 month and 6 months post injury. 
A-C. APP staining of a section from a sham (A) and injured PS1 mouse sacrificed at 1 mo (B) 
or 6 mo (C) post surgery. Scale bar: 2 mm. D-F. Higher magnification of the fimbria/fornix 
(boxes in A-C) shows APP positive varicosities. 
 
We next studied the long-term effects of TBI on Aβ pathology in these mice. 
PanAβ antibody (against amino acids 15-30) and 3D6 antibody (against amino acids 1-5) 
were used for Aβ immunohistochemistry. We found axonal Aβ accumulation in the 
ipsilateral fimbria/fornix of all examined injured 3xTg mice at both 1 month and 6 
months post injury (Figure 7.4 B-C, K-L, N-O). Similar to APP staining, there were 
much less Aβ accumulations at 6 months as compared to 1 month post TBI. Axonal Aβ 
pathology was not observed in injured PS1 mice (Figure 7.4 E-F, H-I), sham PS1 and 
3xTg mice (Figure 7.4 D, J), or in brain sections of injured 3xTg mice when primary 
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antibody was omitted (Figure 7.4 Q).  No extracellular Aβ plaques were observed in 
injured PS1 or 3xTg mice at either time points, even though the staining method used is 
capable of detecting Aβ plaques in an 8 month-old APP/PS1 mice (Jankowsky et al., 
2004) (Figure 7.4 R).  
 
 
Figure 7.4 TBI did not result in the formation of Aβ plaques but caused persistent 
intraa-xonal Aβ accumulations at 1 and 6 months post injury in 3xTg-AD mice. 
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A-C. Low magnification image of a section from a sham (A) and injured 3xTg-AD mouse 
sacrificed at 1 mo (B) or 6 mo (C) post surgery. Scale bar: 2 mm. D-I. Aβ staining in the 
ipsilateral fimbria/fornix (boxes in A-C) of injured PS1 mice using panAβ (D-F) or 3D6 (G-I) 
antibody. Scale bar: 50 µm. No intra-axonal Aβ accumulation was detected. J-O. Intra-axonal 
Aβ accumulation in injured axons of 3xTg-AD mice. P. Schematic of anti-Aβ antibodies used. 
Q. No immunoreactivity is observed in injured fimbria of 3xTg-AD mouse when primary 
antibody (3D6) was omitted. R. Extracellular plaques from a positive control, 8 month-old 
APP/PS1 mouse, detected by 3D6 antibody. 
 
7.4.2 Tau Pathology in 3xTg and PS1 Littermate Controls 
at 1 and 6 months post TBI 
Next, we examined the long-term effects of TBI on tau pathology in these mice, 
since we have shown that TBI can acutely affect tau phosphorylation in 3xTg mice. 
Brain sections from the same mice used for Aβ staining were stained with antibody 
against phospho-tau at S396 and S404 (PHF1 antibody). Intra-axonal punctate PHF1 
tau staining was observed in the ipsilateral fimbria/fornix of both injured PS1 and 3xTg 
mice at 1 month (Figure 7.5 B, E, K), and to a lesser extent at 6 months post injury 
(Figure 7.5 C, F, L). While minute staining was observed in sham 3xTg mice (Figure 
7.5 J), no staining was observed in sham PS1 mice (Figure 7.5 D) and injured 3xTg 
mice when the primary antibody was omitted (Figure 7.5 Q). Perinuclear PHF1 
staining was observed in the ipsilateral amygdala of injured mice at both time points but 
not sham injured mice (Figure 7.5 G-I, M-O).  
   128 
 
 
 
Figure 7.5 TBI did not result in neurofibrillary tangles but caused persistent phopho-tau 
accumulation as detected by PHF1 antibody in the ipsilateral fimbria and amygdala of 
injured mice. 
A-C. Low magnification image of a section from a sham (A) and injured 3xTg-AD mouse 
sacrificed at 1 mo (B) or 6 mo (C) post surgery. Scale bar: 2 mm. D-F. High magnification 
images of the ipsilateral fimbria/fornix (black box in A-C) of PS1 littermates. Scale bar: 50 µm. 
G-I. High magnification of the ipsilateral amygdala (red box in A-C) of PS1 littermates. J-L. 
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Ipsilateral fimbria of 3xTg-AD mice. M-O. Ipsilateral amygdala of 3xTg-AD mice. P. Schematic 
of epitope at which PHF1 antibody detects of full-length tau. Q. Ipsilateral fimbria of an injured 
3xTg-AD mouse when primary antibody is omitted. Punctate tau staining is present in the 
ipsilateral fimbria of injured PS1 and 3xTg-AD mice (arrows).  Cytoplasmic, perinuclear tau 
staining is observed in the ipsilateral amygdala of injured mice (arrow head). 
 
7.4.3 No Formation of Fibrillar Structures in 3xTg and PS1 
Littermate Controls at 1 and 6 months post TBI 
We further asked if TBI could lead to formation of fibrillar structures such as 
plaques and neurofibrillary tangles in the long-term following injury in these mice. Thus, 
X-34 staining was employed.  We did not detect any positive X-34 staining in all mice 
examined, even though signal was observed for the positive control APP/PS1 brain 
sections (data not shown). 
7.5 Discussion 
In summary, we found that controlled cortical impact TBI results in long-term 
behavioral deficits and progressive neuro- and axonal- degeneration in 3xTg and PS1 
littermates. Learning deficits were evidenced by impaired performance of injured 3xTg 
and PS1 mice compared to sham in the hidden platform Morris water maze task. 
Moreover, these impairments persisted up to 6 months following TBI. Hippocampus 
and fimbria ipsilateral to the injury significantly atrophied over 6 months post trauma. 
Interestingly, both the rate and extent of degeneration were similar in injured 3xTg and 
PS1 mice. Furthermore, TBI causes persistent axonal injury as detected by APP in both 
injured 3xTg and PS1 mice. 3xTg mice subjected to TBI also had persistent axonal Aβ 
and phospho-tau pathology in the ipsilateral fimbria, and somatic phospho-tau staining 
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in the ipsilateral amygdala, though the immunoreactivity was markedly reduced 
compared to the acute phase post injury (Tran et al., 2011). Meanwhile, PS1 mice 
subjected to TBI did not exhibit any Aβ pathology, but had persistent phospho-tau 
accumulation in the axonal (fimbria) and somatic (amygdala) compartments.  
It appears unlikely that axonal Aβ pathology contributes to TBI-induced 
neurodegeneration and behavioral deficits in 3xTg mice. The evident neuronal atrophy 
and cognitive impairments of injured PS1 mice in the absence of axonal Aβ pathology 
support this claim. Tau hyperphosphorylation affects its ability to bind and stabilize 
microtubule. This in turn affects normal structural and regulatory functions of the 
cytoskeleton, and ultimately leads to neuronal dysfunction, degeneration, and death. 
Interestingly, chronic accumulation of hyperphosphorylated tau was observed to be a 
common pathological feature in injured 3xTg and mutant PS1 mice. As such, tau 
pathology, but not Aβ, may mediate the progressive neurodegeneration and behavioral 
deficits observed in these mice. Future studies will be required to determine the 
mechanisms underlying TBI-induced tau hyperphosphorylation and whether reducing 
tau phosphorylation is beneficial in the setting of TBI.   
The interaction between TBI and mutant PS1 is intriguing. Various mutants 
PS1, including PS1M146V, have been implicated in neuronal calcium dyshomeostasis, 
which renders neurons more vulnerable to various insults (Koo and Kopan, 2004; 
Mattson, 2010). Thus, our findings that TBI causes similar impairments in 3xTg and 
PS1 mice, though surprising, is not unprecedented.  
APP, which is normally transported along axons via the fast axonal transport 
mechanism, is a robust marker of traumatic axonal injury (Grady et al., 1993; Christman 
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et al., 1994; Graham et al., 1995; Stone et al., 2000, 2001). As such, all injured mice 
examined had positive axonal APP staining. The presence of APP within injured axons 
up to 6 months post injury is also in accord with findings in human TBI (Chen et al., 
2009).   
APP accumulation in injured axons appears necessary but not sufficient for 
axonal Aβ pathology. This is corroborated by extensive APP accumulations observed in 
both injured 3xTg and PS1, but only in injured 3xTg were there axonal Aβ 
accumulations. These results also highlight the importance of the interaction between 
mutant PS1 and APP to generate Aβ the setting of trauma in mice.  
Previous studies from human TBI cases (Smith et al., 2003c) and an 
experimental TBI study in pigs (Smith et al., 1999b) have often found Aβ containing 
plaque-like profiles to be in proximity to Aβ-positive axonal bulbs. These data thus 
leads to the proposal that axonal Aβ accumulation and subsequent release from injured 
axons may contribute to formation of extracellular Aβ plaques in the setting of brain 
trauma. In contrast to this hypothesis, one human TBI study shows that axonal Aβ 
pathology can exist for years following TBI in humans without any effects on 
extracellular plaques (Chen et al., 2009). Our findings of persistent axonal Aβ pathology 
and absence of extracellular plaques at 6 months post trauma in 3xTg mice lends further 
evidence against this hypothesis.  Our study did not address, however, the origin of 
these chronically accumulated Aβ species. It is possible that these are remnants of the 
acute axonal Aβ accumulations observed in these mice at 1 d and 7 d post injury. They 
could also be newly formed Aβ, since long-term co-localizations of Aβ, APP and APP 
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cleaving enzymes, BACE and PS-1, have been previously reported (Chen et al., 2004; 
Uryu et al., 2007; Chen et al., 2009). 
Another possible mechanism through which TBI could induce long-term 
deficits in these mice is via modulation of the inflammatory responses (Loane and 
Byrnes, 2010; Czlonkowska and Kurkowska-Jastrzebska, 2011). Consequently, 
additional studies will be required to determine the roles of astrogliosis in this setting.  
 Taken together, our study shows that a single episode of TBI can initiate long-
term degenerative processes and have detrimental effects on behavioral performance, 
but these may be unrelated.  
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Chapter 8 
Conclusions and Future Directions 
8.1 Conclusions 
In summary, we found that controlled cortical impact TBI in 3xTg-AD mice 
recapitulated two key features observed post TBI in human. First, TBI caused rapid Aβ 
accumulation in injured axons of young 3xTg-AD mice. This intra-axonal Aβ was 
detectable at 1 hour post injury, and continued to rise monotonically through 24 hours. 
This is similar to the intra-axonal Aβ accumulation observed in human TBI patients 
(Smith et al., 2003c; Ikonomovic et al., 2004; Uryu et al., 2007; Chen et al., 2009). No 
such accumulation is expected at this age and none was seen in sham-injured mice. 
Second, TBI increased tau immunoreactivity in three distinct brain regions of 
moderately injured 3xTg-AD mice. The time course was different across regions. In 
particular, puntate tau staining the ipsilateral fimbria and perinuclear tau staining in the 
amygdala had a biphasic response with peaks at 1 hour and 24 hours post TBI. Instead, 
the numbers of tau-positive processes in the contralateral CA1 started to increase at 12 
h post injury. Total tau immunoreactivity in the ipsilateral CA1 was not significantly 
affected by TBI. This may be because of substantial damage to this region, which could 
have caused tau release into the extracellular space, where it could not be detected 
immunohistochemically. Further, there was also immunohistochemical and biochemical 
evidence for increased tau phosphorylation induced by TBI at several epitopes. 
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Next, we found that systemic inhibition of γ-secretase activity by CmpE 
effectively blocked the post-traumatic Aβ accumulation in 3xTg-AD mice at both 24 h 
and 7 d post injury. However, Aβ blockade did not affect tau pathology accelerated by 
TBI at either time points. These data suggest that Aβ and tau do not interact in the 
setting of brain trauma. 
Furthermore, we showed that the finding of post-traumatic Aβ accumulation in 
3xTg-AD mice was recapitulated in a different transgenic mouse model of Alzheimer’s 
disease, APP/PS1. We also found TBI to accelerate tau pathology in transgenic mice 
carrying only TauP301L mutation at 24 hours. This finding further supports the 
independent relationship between Aβ and tau in the setting of TBI. 
Additionally, we showed that TBI resulted in different regional patterns of 
activation of a number of tau kinases. The primary site of kinase activation and 
accumulation was within injured axons, particularly the ipsilateral fimbria/fornix. The 
stress activated kinase, c-jun-N-termnial kinase (JNK) was markedly activated in this 
region compared to the rest of the examined kinases. JNK was also activated in cortical 
and thalamic regions surrounding the impact site. Notably, JNK appeared to play a 
critical role in TBI-induced tau hyperphosphorylation, as activated JNK colocalized 
with phospho-tau, and inhibition of JNK activity reduced tau phosphorylation in 
injured axons. 
Lastly, we found that controlled cortical impact TBI resulted in long-term 
behavioral deficits and progressive neuro- and axonal- degeneration in 3xTg-AD mice. 
However, these deficits cannot be attributed to the Aβ and tau pathologies observed 
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acutely in these mice post TBI, since injured PS1 littermate controls exhibited similar 
degree of neurodegeneration and cognitive impairments.  
8.2 Future Directions 
Traumatic axonal injury (TAI) may contribute greatly to morbidity and cognitive 
dysfunction following TBI. TAI is thought to cause axonal transport deficits, resulting 
accumulations of various organelles and proteins, including neurofilaments and APP 
(Povlishock and Christman, 1995). Our data provide further evidence that axonal 
transport deficits induced by TAI may be responsible for the accumulation of Aβ, tau, 
and tau kinases. As a result, future studies aiming at reducing axonal transport deficits 
will likely prove beneficial in the setting of TBI. The use of microtubule-stabilizing 
drugs such as paclitaxel and epothilone D (EpoD) has been shown to improve 
microtubule density, ameliorate axonal transport defects, and improve motor and 
cognitive deficits in tau transgenic mice (Zhang et al., 2005; Brunden et al., 2010b). 
Notably, mice which received either 1 mg/kg or 3 mg/kg of EpoD weekly for 3 
months did not exhibit any overt side-effects (Brunden et al., 2010b). Therefore, similar 
dosages and treatment regimen of this compound could be employed to treat both 
transgenic and wildtype mice following controlled cortical impact TBI. It will also be 
important to evaluate the effectiveness of this drug in a milder injury model, since the 
majority of TBI cases are mild. In fact, the repetitive closed-skull impact model recently 
developed by me and characterized by Dr. Shitaka from our lab is a good candidate 
model. We have reported that 2 consecutive impacts 24 hours apart can cause persistent 
axonal injury and microglial activation in absence of gross parenchymal damage and 
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overt cell death (Shitaka et al., 2011). Electron microscopic and electrophysiological 
studies can be used to assess structural and functional integrity of CNS axonal tracts 
such as the corpus callosum, fimbria/fornix, and optic nerve following EpoD or vehicle 
treatment in injured mice. Further, since abnormal signal in diffusion tensor magnetic 
resonance imaging, which detects water diffusion along white matter, has been shown 
to correlate with TAI in alive but injured mice (Mac Donald et al., 2007a), this imaging 
modality could be used as an additional outcome measures of the effectiveness EpoD 
treatment in rescuing transport deficits in experimental TBI.  
The role of JNK in TBI-induced tau pathology will require rigorous testing in 
future studies. First, a more detailed time course of JNK activation following controlled 
cortical impact in 3xTg-AD mice will provide useful information for determination of 
therapeutics windows of JNK inhibition. For this purpose, separate groups of injured 
mice could be sacrificed at 0.5, 1, 3, 6, and 12 hours, and at 3 and 7 days post injury. 
JNK activation can be assessed via IHC or WB with antibody against phospho 
(activated) JNK, or by western blotting against phospho c-jun, or by pull down kinase 
assay as described (Barr et al., 2002).  
Second, we initially used the D-stereoisomer of the JNK inhibiting peptide (D-
JNKi1) because of its reported long half-life: FITC-labeled D-JNKi1 peptides were 
present up to two weeks following application to insulin-secreting cell line (Bonny et al., 
2001). However, since JNK has been reported to involve in both axon degeneration 
(Miller et al., 2009) and regeneration (Nix et al., 2011) following axotomy, it may be 
better to inhibit JNK during the time when its activity is detrimental. As such, the use of 
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L-JNKi1 (L-stereoisomer), which has a shorter half-life (less than 24 hours in cell 
culture) (Bonny et al., 2001), should be tested.  
Third, delivery of these peptide inhibitors via intraperitoneal injections should 
be considered, since this delivery method has been shown to effectively inhibit JNK 
activity in the mouse models of ischemia (Borsello et al., 2003b; Nijboer et al., 2010).  
Next, it will be interesting to determine the upstream signals that activate JNK 
in the setting of TBI. As a stress-activated kinase, JNK is readily activated by various 
cytokines (Kyriakis and Avruch, 2001). Furthermore, glutamate has been shown to 
activate JNK (Borsello et al., 2003a; Choi, 2010), and JNK3-/- protected hippocampal 
cells from glutamate-induced excitoxicity (Yang et al., 1997). Both glutamate and 
cytokines such as TNF-α and IL-1β (Lu et al., 2009) are also highly upregulated 
following brain trauma. Therefore, glutamate receptor antagonists, TNF-α, and IL-1β 
inhibitors could be employed to determine if these molecules are activators of JNK.  
In a pilot study, I found that controlled cortical impact TBI significantly increase 
caspase-6 but not caspase-3 activity in injured wildtype and 3xTg-AD mice. I also found 
cleaved (activated) caspase 6 to localize in injured axons of 3xTg-AD mice. Since stress-
activated p38 kinase, but not JNK, has been shown to activate caspase 3 in neurons 
treated with nitric oxide (Ghatan et al., 2000), a product of glutatmate-induced 
excitotoxicity, it is probable that JNK, but not p38, may be involved in caspase 6 
activation in axons. Interestingly, caspase 6 activation has been implicated in axonal 
degeneration in developing neuronal cultures (Nikolaev et al., 2009). Thus, it will be 
interesting to determine if similar signaling pathway is involved in axon degeneration in 
adult mice following TBI. Toward this end, brain homogenates from injured mice 
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treated with JNK inhibitor peptide could be used to examine caspase activity using 
VEID-pNA colorimetric assay kit (R&D Systems). Alternatively, treatment of injured 
mice with a caspase 6 specific inhibitor, VEID-fmk (Calbiochem), could be studied to 
determine if it could prevent or delay axon degeneration.  
Tau pathology is a major pathological hallmark of dementia pugilistica or 
chronic traumatic encephalopathy (Roberts et al., 1990; Schmidt et al., 2001; McKee et 
al., 2009), which results from a life-long history of concussive injuries. Thus, it will be 
important to determine if JNK mediates tau phosphorylation and accumulation in 
repetitive TBI. JNK activation can be assessed in post-mortem tissues of athletes and 
boxers. JNK roles in acceleration tau pathology in tau only transgenic mice subjected to 
repetitive closed-skull impacts will be an important future direction. Moreover, although 
there exists a strong link between ApoE genotypes and TBI outcomes (Sorbi et al., 
1995; Teasdale et al., 1997; Friedman et al., 1999; Lichtman et al., 2000; Diaz-Arrastia et 
al., 2003; Teasdale et al., 2005; Zhou et al., 2008), differential interaction between ApoE 
genotypes and microtubule and tau (Horsburgh et al., 2000), and TBI and tau 
pathology, there is virtually no experimental model which investigates the interaction 
between tau, ApoE genotypes and TBI. As such, it will be important and will 
significantly advance the field to study the chronic effect of repetitive TBI in tau and 
ApoE-2, -3, and -4 knockin or tau and ApoE knockout double transgenic mice. 
Lastly, future research should also focus on the roles of GSK-3 on tau 
phosphorylation and axon degeneration. I found activated GSK-3 to localize to 
pericontusional CA1 and white matter structures of injured 3xTg-AD mice. It will be 
important to determine if TBI increases GSK-3 activity using GSK-3 kinase activity as 
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described (Noble et al., 2005), and if inhibition of GSK-3 activity using lithium or small 
molecule inhibitor of GSK-3 will reduce TBI-induced tau pathology and axon 
degeneration. It may be possible that a combined GSK-3 and JNK inhibition regimen 
will be required to see functional and behavioral benefits of reduction tau pathology in 
the setting of TBI.        
 
Concluding Remarks: 
TBI is a major environmental risk factor for subsequent development of AD. 
Thus, it is important to understand the underlying link between TBI and AD. During 
my thesis, I have found that controlled cortical impact TBI caused acute accumulation 
of Aβ, tau, and phospho-tau. While it is unlikely that acute Aβ pathology contributes 
negatively to behavioral outcomes, the role of tau pathology is still to be determined. 
While much work will be required in future studies, identification of JNK as a possible 
tau kinase in the setting of TBI provides a starting point for research into mechanisms 
underlying TBI-induced tau pathology, and for determination of whether reducing tau 
pathology would ameliorate adverse outcomes following TBI.   
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